Tuesday, November 14, 2023
Print Entire 2023 Program:
![]() |
|
SESSION 1 SCHEDULE | |
Tuesday
SESSION 1:
PROGRESS IN CORONARY ARTERY STENTING, TRANSCATHETER VALVE REPLACEMENT, AND TREATMENT OF ASCENDING AORTIC DISEASE
Moderators:TBD
|
|
x | |
6:45 AM - 6:50 AM | Opening Remarks |
Presenter(s):Frank J. Veith, MD | |
CORONARY STENTS | |
6:50 AM - 6:55 AM | What Is New In Coronary Artery Stenting: What Is The Role For Bare Metal Stents |
Presenter(s):Martin B. Leon, MD | |
6:56 AM - 7:01 AM | What Is New With Treatment Outcomes For Left Main Coronary Artery Disease: Advantages And Limitations Of PCI And CABG: Which Has Better Long-Term Survival |
Presenter(s):Gregg W. Stone, MD | |
TRANSCATHETER HEART VALVES | |
7:02 AM - 7:07 AM | Update On The Status Of Transcatheter Mitral Valve Replacement/Repair (TMVR) |
Presenter(s):Juan F. Granada, MD | |
7:08 AM - 7:13 AM | DEBATE: What Is New With Transcatheter Aortic Valve Replacement (TAVR): What Are Its Limitations: A Cardiologist’s View |
Presenter(s):Martin B. Leon, MD | |
7:14 AM - 7:19 AM | DEBATE: Update On Current State Of TAVR: A Cardiac Surgeon’s View: What Is The Role Of Surgery In Aortic Valve Disease |
Presenter(s):Ali B. Khoynezhad, MD, PhD | |
THE ASCENDING AORTA | |
7:20 AM - 7:25 AM | Progress In Endovascular Graft Treatment Of Ascending Aortic Lesions: What New Grafts Are Being Developed: What Problems Exist: Will They Be Overcome And Will This Segment Of The Aorta Be Conquered Endovascularly |
Presenter(s):Rodney A. White, MD | |
7:26 AM - 7:31 AM | Endovascular Treatment Of Type A Aortic Dissections (TAADs) In 2023: What Is Here And What Is Coming: Experience With Ascending Aortic Endografting |
Presenter(s):Eric E. Roselli, MD | |
7:32 AM - 7:37 AM | Progress In Endovascular Devices For Repairing Lesions Of The Ascending Aorta And The Aortic Valve With The Endo-Wheat And The Endo-Bentall Concept |
Presenter(s):Ali B. Khoynezhad, MD, PhD | |
7:38 AM - 7:43 AM | Current And Future Status Of Ascending Aortic Endograft Repairs: Devices And Experience With Endo-Wheat And Endo-Bentall Procedures |
Presenter(s):Nimesh D. Desai, MD, PhD | |
7:44 AM - 7:50 AM | Panel Discussion |
END OF SESSION 1 | |
SESSION 2 SCHEDULE | |
Tuesday
SESSION 2:
PROGRESS IN THE TREATMENT OF AORTIC ARCH LESIONS AND AORTIC DISSECTIONS
Moderators:TBD
|
|
x | |
7:50 AM - 7:55 AM | Current Status Of Open Aortic Arch Repair: What Is The Benchmark That Endo And Hybrid Techniques Must Compete With |
Presenter(s):Anthony L. Estrera, MD | |
7:56 AM - 8:01 AM | Update On Hybrid Repair Of Aortic Arch And Thoracic Aortic Aneurysms Using ThoraFlex (Hybrid) And Relay Devices For Frozen Elephant Trunk (FET) And TEVAR: Indications And Results |
Presenter(s):Joseph S. Coselli, MD / Ourania Preventza, MD | |
8:02 AM - 8:07 AM | Update On Endovascular Arch Repair With Cook 2- Or 3-Branched Device For Lesions Involving The Entire Aortic Arch: Retrograde Versus Antegrade Insertion Of Arch Branches: Advantages Of A Fully Percutaneous Approach |
Presenter(s):Stephan Haulon, MD | |
8:08 AM - 8:13 AM | Long-Term Results With 2-Branched Endograft (Relay – Terumo Aortic) And Single Branched Device (Nexus – Endospan) For Treatment Of Zone 0 Arch Lesions |
Presenter(s):Toru Kuratani, MD, PhD | |
8:14 AM - 8:19 AM | Update On Relay Branch Device (Terumo Aortic) For Arch Lesion Endovascular Repairs: Advantages, Limitations And Results |
Presenter(s):Vicente Riambau, MD, PhD / Ciro Ferrer, MD, PhD / Martin Czerny, MD | |
8:20 AM - 8:25 AM | A New Device For Endovascular Repair Of Aortic Arch Aneurysms: Advantages And Early Clinical Experience |
Presenter(s):Qingsheng Lu, MD / Zaiping Jing, MD | |
8:26 AM - 8:31 AM | Update On Total And Partial Aortic Arch Lesion Repairs With The Gore TAG Single Branch Endograft: An Off-The-Shelf (OTS) Device For Revascularizing Arch Branches: Experience To Date, Advantages And Limitations |
Presenter(s):Michael D. Dake, MD / Himanshu Patel, MD / Joseph E. Bavaria, MD | |
8:32 AM - 8:37 AM | How Best To Treat TBADs Extending Into The Arch Or Ascending Aorta; When Open, When Endo, When Hybrid |
Presenter(s):I-Hui Wu, MD, PhD | |
8:38 AM - 8:43 AM | A New Device For Endovascular Aortic Arch Reconstruction: Characteristics, Advantages And Early Clinical Results |
Presenter(s):Chang Shu, MD | |
8:44 AM - 8:49 AM | How Best To Treat Aortic Arch Lesions: Customized Versus Off-The-Shelf (Chimney) Versus Physician Modified Endografts: Is Open Ever Necessary |
Presenter(s):Nicola Mangialardi, MD | |
8:50 AM - 8:55 AM | Value Of Ascending Aortic Banding As Primary Or Adjunctive Treatment For Aortic Arch Lesions |
Presenter(s):Chun Che Shih, MD, PhD | |
8:56 AM - 9:02 AM | Panel Discussion |
END OF SESSION 2 | |
SESSION 3 SCHEDULE | |
Tuesday
SESSION 3:
PROGRESS IN THE ENDOVASCULAR TREATMENT OF AORTIC DISSECTIONS: REPORTING STANDARDS, CLASSIFICATION SYSTEMS, STABILIZE, AND MORE
Moderators:TBD
|
|
x | |
9:02 AM - 9:07 AM | Guideline Update On The SVS-STS Aortic Dissection Reporting Standards And Classification System: How Do They Help In Precisely Determining High Risk TBAD Patients |
Presenter(s):Joseph V. Lombardi, MD, MBA | |
9:08 AM - 9:13 AM | Important Bullet Points Regarding Aortic Dissections From The European Association For Cardiothoracic Surgery: What Is New About Them |
Presenter(s):Martin Czerny, MD | |
9:14 AM - 9:19 AM | Imperfect TEVAR Stent-Graft Performance As A Cause Of Aortic Remodeling And How It Can Be Prevented And Treated |
Presenter(s):Weiguo Fu, MD | |
9:20 AM - 9:25 AM | New Findings Regarding The STABILISE Concept For Treating Acute And Chronic TBADs By Disrupting The Intimal Flap By Overdilating The Distal Bare Stent: How It Works, Precautions, And Should It Be The Treatment Of Choice |
Presenter(s):Jean-Marc Alsac, MD, PhD | |
9:26 AM - 9:31 AM | Updated Experience With The STABILISE Technique For Acute And Subacute TBADs: Indications, Technical Tips, Precautions And Results |
Presenter(s):Germano Melissano, MD / Andrea Kahlberg, MD / Roberto L.V. Chiesa, MD | |
9:32 AM - 9:37 AM | Dual Lumen Interventions To Promote False Lumen Thrombosis In Chronic Aortic Dissections: The FLIRT Procedure: What Is It; When Is It Useful; How To Do It |
Presenter(s):Christoph A. Nienaber, MD, PhD | |
9:38 AM - 9:43 AM | There Will Always Be A Need For Open Repair For Post-Dissection TAAAs: In What Circumstances |
Presenter(s):Hazim J. Safi, MD | |
9:44 AM - 9:49 AM | Distal Stent-Graft Induced New Re-Entry Tears (SINEs) With TEVAR Treatment Of TBADs: Prevention By Avoiding Oversizing And Ballooning And Using Tapered Endografts |
Presenter(s):Ludovic Canaud, MD, PhD | |
9:50 AM - 9:55 AM | The Impact Of Distal Stent-Graft Induced New Entry Tears On Aortic Remodeling Of Chronic TBADs: How To Prevent And Treat Them |
Presenter(s):Chun Che Shih, MD, PhD | |
9:56 AM - 10:01 AM | Highlights From The New SVS, AATS, AHA, ACC, ACR, STS, SVM, SCAI, SCA Aortic Disease Guidelines: What Are The Key Differences |
Presenter(s):James H. Black, III, MD | |
10:02 AM - 10:07 AM | International Experience With Endovascular Treatment Of Complex Aortic Diseases In Patients With Connective Tissue Disease (CTD) Including Loeys-Dietz And Ehlers-Danlos Syndromes: What Is Its Role |
Presenter(s):Anders Wanhainen, MD, PhD | |
10:08 AM - 10:14 AM | Panel Discussion |
10:14 AM - 10:24 AM | Break – Visit Exhibits And Pavilions (2nd and 3rd Floors) |
END OF SESSION 3 | |
SESSION 4 SCHEDULE | |
Tuesday
SESSION 4:
MORE NEW DEVELOPMENTS IN THE TREATMENT OF TBADs, THORACIC AORTIC DISEASE AND THORACOABDOMINAL ANEURYSMS (TAAAs)
Moderators:TBD
|
|
x | |
10:24 AM - 10:29 AM | When Should Fully Open Repair Be First Line Treatment For TAAAs And When Should A Hybrid (Endograft Proximal + Open Distal) Be The Preferred Treatment: How To Do The Latter |
Presenter(s):Margaret C. Tracci, MD, JD | |
10:30 AM - 10:35 AM | New Strategies And Indications For Open TAAA Repair Including Failed EVAR And F/B/EVAR: Technical Tips And Results |
Presenter(s):Germano Melissano, MD / Andrea Kahlberg, MD / Roberto L.V. Chiesa, MD | |
10:36 AM - 10:41 AM | Update On Aortic Arch Repairs With Frozen Elephant Trunk (FET) Followed By Open Or Endo Extensions For TAAA Repairs: Techniques And Outcomes; Importance Of Staging |
Presenter(s):Michael J. Jacobs, MD / Barend M.E. Mees, MD, PhD, FEBVS / Geert Willem H. Schurink, MD, PhD | |
10:42 AM - 10:47 AM | New Findings From The STABLE I And II Trials: What Are The Short And Long-Term Benefits And Limitations Of A Distal Bare Stent Combined With A Proximal Covered Stent (The Petticoat Procedure): Update On Aortic Remodeling |
Presenter(s):Joseph V. Lombardi, MD, MBA | |
10:48 AM - 10:53 AM | 25 Years Of Data From The IRAD Registry (International Registry Of Acute Aortic Dissection): How Has Treatment Evolved; What Lessons Have Been Learned: What Key Questions Remain |
Presenter(s):Santi Trimarchi, MD, PhD | |
10:54 AM - 10:59 AM | F/B/EVAR For TAAAs Degenerative And Post TBAD: The Good, Bad And Ugly (Complications And How To Prevent Them: Value Of The BeBack Catheter To Cross The Dissection Flap |
Presenter(s):Eric L.G. Verhoeven, MD, PhD / Athanasios Katsargyris, MD | |
11:00 AM - 11:05 AM | Experience With Inner And Outer Branched Endografts And The t-Branch OTS Device (Cook) To Treat TAAAs After TBADs: Technical Tips And Results |
Presenter(s):Marcelo Ferreira, MD | |
11:06 AM - 11:12 AM | Panel Discussion |
11:12 AM - 11:17 AM | Update On The Endovascular Treatment Of Ascending Aortic Disease With The Gore Ascending Aortic Endograft: Advantages, Limitations And Results From The ARISE Trial |
Presenter(s):Ali Azizzadeh, MD | |
11:18 AM - 11:23 AM | Unitary Manifold Endograft System For Complex Type 4 TAAAs, Aneurysms With Chronic TBADs, Ruptured Complex AAAs And Failed Prior EVAR Repairs: How Does It Work And Up To 10-Year Results |
Presenter(s):Patrick W. Kelly, MD | |
11:24 AM - 11:29 AM | Type A Aortic Dissection With Malperfusion: The Guidelines May Be Wrong: TEVAR Should Be The First Order Of Business Before Fixing The Tear In The Ascending Aorta: Why And What Are The Dangers |
Presenter(s):Firas F. Mussa, MD | |
11:30 AM - 11:35 AM | Improved Aortic Remodeling With TEVAR And A Distal Bare Metal Stent In Acute Complicated TBAD |
Presenter(s):Christoph A. Nienaber, MD, PhD | |
11:36 AM - 11:41 AM | Endovascular Thermal Septotomy Of The Dissection Flap With An Electrocautery Activated Guidewire To Eliminate And Prevent Enlargement Of The False Lumen To Treat Chronic TBADs |
Presenter(s):Carlos H. Timaran, MD | |
11:42 AM - 11:47 AM | Fenestrated TEVAR Devices For The Treatment Of Post Dissection Aortic Arch False Lumen Aneurysms: What Devices Are Available, How Do They Work And Results |
Presenter(s):Nicola Mangialardi, MD | |
11:48 AM - 11:53 AM | With Acute Type B Aortic Intramural Hematomas (IMHs): When Is TEVAR Indicated: How Long Should Treatment Be Delayed For Optimal Outcomes: Earlier TEVAR Has More Adverse Events |
Presenter(s):Jean M. Panneton, MD | |
11:54 AM - 12:00 PM | Panel Discussion |
12:00 PM - 1:00 PM | Lunch Break - Visit Exhibits And Pavilions (2nd and 3rd Floors) |
END OF SESSION 4 | |
SESSION 5 SCHEDULE | |
Tuesday
SESSION 5:
NEW DEVELOPMENTS IN ABDOMINAL AORTIC ANEURYSM (AAA) ETIOLOGY AND TREATMENT, EVAR AND EVAS (ENDOVASCULAR ANEURYSM SEALING
Moderators:TBD
|
|
x | |
1:00 PM - 1:05 PM | Failing EVARs Are An Enlarging Epidemic: Etiology And How Best To Prevent And Treat The Problem: Can Cloud Based Fusion Help |
Presenter(s):Murray L. Shames, MD | |
1:06 PM - 1:11 PM | What Evidence Really Matters In Evaluating EVAR Results: What Is The Best Type Of Evidence To Compare EVAR With Open Repair: RCTs May Not Reflect Reality As Well As Other Methods: The NICE Guidelines Prove It |
Presenter(s):Matt M. Thompson, MD | |
1:12 PM - 1:17 PM | Are There Registry Differences In Neck Behavior And AAA Sac Shrinkage After Excluder And Endurant Endografts: Why We Need A Head-To-Head Randomized Comparison After EVAR With The 2 Endografts: The ADVANCE RCT |
Presenter(s):Marc L. Schermerhorn, MD / Hence J.M. Verhagen, MD, PhD | |
1:18 PM - 1:23 PM | Diabetes Versus COVID-19: How Should Both Modify AAA Treatment Or Its Planning |
Presenter(s):Ronald L. Dalman, MD | |
1:24 PM - 1:29 PM | How Does Metformin Work To Slow AAA Growth: Is It The Reason For Decreased AAA Incidence In Diabetes |
Presenter(s):Kak Khee Yeung, MD, PhD | |
1:30 PM - 1:35 PM | The Metformin For AAA Growth Inhibition (MAAGI) Multicenter Trial: Design And Preliminary Results: Will The Drug Help In The Treatment Of Small AAAs |
Presenter(s):Anders Wanhainen, MD, PhD | |
1:36 PM - 1:42 PM | Panel Discussion |
1:42 PM - 2:47 PM | A Note Of Caution Regarding Nellix Endografts And EVAS From The European Society For Vascular Surgery (ESVS) Guidelines Committee |
Presenter(s):Mr. Jonathan R. Boyle, MD, FRCS / Nikolaos Tsilimparis, MD, PhD / Isabelle Van Herzeele, MD, PhD / Anders Wanhainen, MD, PhD | |
1:48 PM - 1:53 PM | Decreased AAA Sac Diameter After EVAR Is Associated With Good Outcomes While Sac Diameter Stability Is Not: Is Diameter The Best Method To Determine Sac Shrinkage Or Should We Be Measuring Sac Volume More |
Presenter(s):Andres Schanzer, MD | |
1:54 PM - 1:59 PM | Sac Dynamics After EVAR Influence Long-Term Survival: What Can Be Done To Improve AAA Sac Shrinkage: Filling The Sac With Polymer Plugs From Shape Memory Medical Promotes Sac Shrinkage: Update On The AAA-SHAPE-NLD Study |
Presenter(s):Michel M.P. Reijnen, MD, PhD / Andrew Holden, MBChB | |
2:00 PM - 2:05 PM | Update On Long-Term Results From The DREAM RCT Comparing EVAR With Open Repair For AAAs Suitable For Both: Adverse Neck Anatomy (Short, Wide, Angulated) Was Associated With Increased Reintervention And Mortality Rates Equally After Open And Endo Repairs: How Should This Influence Treatment |
Presenter(s):Jan D. Blankensteijn, MD | |
2:06 PM - 2:11 PM | Management Of The Internal Iliac Artery With Extensive Aortoiliac Aneurysms In The Era Of Iliac Branched Devices: Is There Any Role For Open Surgery |
Presenter(s):Heron E. Rodriguez, MD | |
2:12 PM - 2:17 PM | Danger Of Performing EVAR In Patients With Visceral Artery (SMA) Occlusive Disease: What Can Happen And How Should It Be Avoided |
Presenter(s):Karan Garg, MD / Neal S. Cayne, MD / Carlos H. Timaran, MD / Frank J. Veith, MD | |
2:18 PM - 2:23 PM | Which AAA Patients Should Get Open Repair (OR) In 2023: Young Healthy Patients With Large AAAs Do Better With OR: But EVAR Outcomes Are Improving While OR Outcomes Are Not |
Presenter(s):Marc L. Schermerhorn, MD | |
2:24 PM - 2:30 PM | Panel Discussion |
2:30 PM - 2:40 PM | Break – Visit Exhibits And Pavilions (2nd and 3rd Floors) |
END OF SESSION 5 | |
SESSION 6 SCHEDULE | |
Tuesday
SESSION 6:
MORE ABOUT AAAs AND EVAR, STANDARD AND COMPLEX: UPDATES ON THE UK NICE AAA GUIDELINES AND OTHER AORTIC PATHOLOGY
Moderators:TBD
|
|
x | |
2:40 PM - 2:45 PM | The Safe-AAA Study Emphasizes The Importance Of Ongoing Surveillance And Continuing EVAR Device Risk: Some EVAR Endografts Have Been Found To Have More Late Risks Than Others |
Presenter(s):Philip P. Goodney, MD, MS / Eric A. Secemsky, MD, MSc | |
2:46 PM - 2:51 PM | Review Of All Recent AAA Guidelines: Do They Support Or Refute The NICE AAA Guidelines |
Presenter(s):Andrew W. Bradbury, MD, FRCSEd | |
2:52 PM - 2:57 PM | How Have The NICE AAA Guidelines Influenced The Performance Of EVAR In The UK: Are The Guidelines Wrong And Can They Be Fixed |
Presenter(s):Michael P. Jenkins, MBBS, BSc, MS, FRCS, FEBVS | |
2:58 PM - 3:03 PM | Why The NICE AAA Guidelines Are The Way They Are: Bias Has Played A Role As It Does In Many Things: Randomized Controlled Trials (RCTs) Can Be Misleading |
Presenter(s):Frans L. Moll, MD, PhD | |
TOPICS RELATED TO INFRARENAL AORTIC LESIONS AND AAAs | |
3:04 PM - 3:09 PM | Spontaneous Infrarenal Acute Aortic Syndrome: What Is It And Why Is It Best Treated With A Unibody Stent-Graft |
Presenter(s):Felice Pecoraro, MD | |
3:10 PM - 3:15 PM | Observation Of Small AAAs (<5.0 cm) Is Safe, Predictable And Does Not Lessen EVAR Options: Are There Exceptions And Does AAA Volume Matter |
Presenter(s):Jon S. Matsumura, MD | |
3:16 PM - 3:21 PM | Should Saccular AAAs Be Fixed At A Smaller Diameter Than Fusiform AAAs: How To Measure Saccular AAA Diameter: Should It Include The Normal Aorta Or Not |
Presenter(s):Frans L. Moll, MD, PhD | |
3:22 PM - 3:27 PM | Why And When EVAR Is NOT The Best Treatment For All AAAs Even With Favorable EVAR Anatomy: When Open And When No Treatment Is Better |
Presenter(s):Fabio Verzini, MD, PhD, FEBVS | |
TOPICS RELATED TO COMPLEX AORTIC PATHOLOGY | |
3:28 PM - 3:33 PM | Value Of IVUS In Treating Complex Aortic Pathology |
Presenter(s):Tara M. Mastracci, MD | |
3:34 PM - 3:39 PM | Early Experience With Off-The-Shelf Inner Branch Stent Grafting For Complex AAAs And TAAAs |
Presenter(s):Dittmar Boeckler, MD | |
3:40 PM - 3:45 PM | With Failed EVAR, When Is F/EVAR The Best Treatment: Tips And Tricks For Performing It Successfully |
Presenter(s):Andres Schanzer, MD | |
3:46 PM - 3:56 PM | Panel Discussion |
END OF SESSION 6 | |
SESSION 7 SCHEDULE | |
Tuesday
SESSION 7:
MORE NEW DEVELOPMENTS IN THE TREATMENT OF AORTIC THORACIC PATHOLOGY; STROKE PREVENTION WITH TEVAR
Moderators:TBD
|
|
x | |
3:56 PM - 4:01 PM | How To Predict Failed Proximal EVAR Fixation With Short Necked AAAs So Initial Treatment Should Be With F/EVAR Or Ch/EVAR |
Presenter(s):Martin R. Back, MD | |
4:02 PM - 4:07 PM | Update On Prevention Of Gas Emboli And Stroke With TEVAR: How Important Is CO2 Flushing And Other Measures: Progress With The STEP 2 Study |
Presenter(s):Tilo Koelbel, MD, PhD / Stephan Haulon, MD | |
4:08 PM - 4:13 PM | High Risk Features In Uncomplicated TBAD Patients: How Do We Know They Justify Elective TEVAR |
Presenter(s):Joseph V. Lombardi, MD, MBA / Jeffrey P. Carpenter, MD | |
4:14 PM - 4:19 PM | Current Role Of Physician Modified Endografts (PMEGS) For Total Endovascular Aortic Arch Repair |
Presenter(s):Carlos H. Timaran, MD | |
4:20 PM - 4:25 PM | How To Prevent Bird Beaking And Type I Endoleaks With TEVAR In The Aortic Arch: How To Size TEVAR Grafts Optimally And Does It Matter |
Presenter(s):Thomas L. Forbes, MD | |
4:26 PM - 4:31 PM | How Best To Treat TBADs Extending Into The Aortic Arch Or Ascending Aorta: When Open, When Endo, When Hybrid: Technical Trips |
Presenter(s):I-Hui Wu, MD, PhD | |
4:32 PM - 4:37 PM | Endovascular Aortic Arch Interventions: Hybrid Options Versus Total Endovascular Repair |
Presenter(s):Cherrie Z. Abraham, MD | |
4:38 PM - 4:43 PM | Long-Term (>5 Years) Good Results Of The Medtronic Valiant Captiva Endografts For TEVAR In TBAD Patients: Advantages And Disadvantages |
Presenter(s):Joseph E. Bavaria, MD | |
4:44 PM - 4:49 PM | How To Treat Aortic Dissections With An Entry Tear In The Aortic Arch: Can Ancillary Techniques Help |
Presenter(s):Santi Trimarchi, MD, PhD | |
4:50 PM - 4:56 PM | Panel Discussion |
END OF SESSION 7 | |
SESSION 8 SCHEDULE | |
Tuesday
SESSION 8:
MORE NEW DEVELOPMENTS REGARDING TBADs AND TEVAR: NATURAL HISTORY; NEED FOR AND TIMING OF TEVAR FOR ACUTE UNCOMPLICATED TBADs
Moderators:TBD
|
|
x | |
4:56 PM - 5:01 PM | TBD |
5:02 PM - 5:07 PM | What Does Endovascular Aortic Repair Do To Cardiac And Coronary Artery Function: Does The Position Of The Graft Make A Difference: Do We Need A Compliant Endograft |
Presenter(s):Rachel E. Clough, PhD, FRCS | |
DEBATE ON TREATMENT OF ACUTE UNCOMPLICATED TBADs | |
5:08 PM - 5:13 PM | DEBATE: With Uncomplicated Acute TBADs, The Case For Waiting 2-6 Weeks From Onset For TEVAR And Then Limiting Aortic Coverage |
Presenter(s):Mark A. Farber, MD | |
5:14 PM - 5:19 PM | DEBATE: With Uncomplicated TBADs, The Case For Early TEVAR With Extensive Aortic Coverage In Most Patients |
Presenter(s):William D. Jordan Jr., MD / Brad Leshnower, MD | |
5:20 PM - 5:25 PM | How To Prevent Abdominal Extension Of The False Lumen And TAAAs With TBADs: Does Early TEVAR Help: What Other Techniques Show Promise |
Presenter(s):Rodney A. White, MD | |
5:26 PM - 5:31 PM | The Indication For TEVAR Is More Important Than Its Timing In Predicting Outcomes With Acute Uncomplicated TBAD Patients: When Is Medical Treatment Alone Indicated |
Presenter(s):Ali Azizzadeh, MD | |
5:32 PM - 5:37 PM | With TBADs, Is True Lumen Compression Ever So Severe That It Negatively Influences TEVAR Deployment Or Performance: How Can It Be Managed |
Presenter(s):Sara L. Zettervall, MD / Benjamin W. Starnes, MD | |
5:38 PM - 5:43 PM | With TBADs, Distal Fenestrations Are Important: How Should they Be Treated |
Presenter(s):Frank R. Arko, MD | |
5:44 PM - 5:49 PM | With Acute Type A Aortic Dissection (TAAD) And End-Organ Ischemia, Which Should Come First – Aortic Repair Or Restoration Of Branch Perfusion: How To Accomplish The Latter |
Presenter(s):David M. Williams, MD | |
5:50 PM - 5:55 PM | Re-Entry Specific Endovascular Therapy (RESET), i.e. TEVAR Plus Dealing With Re-Entry Tears: It Promotes False Lumen Thrombosis, Aortic Remodeling And Improves Outcomes: How To Do It |
Presenter(s):Jean M. Panneton, MD | |
5:56 PM - 6:02 PM | Panel Discussion End of Program A |
END OF SESSION 8 | |
SESSION 9 SCHEDULE | |
Tuesday
SESSION 9:
PROGRESS IN VASCULAR ROBOTICS, LAPAROSCOPY, GUIDANCE SYSTEMS AND SIMULATION
Moderators:TBD
|
|
x | |
6:40 AM - 6:43 AM | Opening Remarks |
Presenter(s):Enrico Ascher, MD | |
6:44 AM - 6:49 AM Power Point Presentation with Synched Audio |
Focus On Radiation Protection During Simulation-Based Training Improves Both Correct Behavior And Procedural Performance: Proven By A Randomized Comparison |
Presenter(s):Lars B. Lonn, MD, PhD | |
6:50 AM - 6:55 AM | How Can Ex Vivo Training With Simulators Decrease Vascular Complications And Improve Outcomes |
Presenter(s):Michael E. Barfield, MD | |
6:56 AM - 7:01 AM | Laparoscopic Aortic Surgery: How I Did It Routinely And Why I Stopped After More Than 150 Cases |
Presenter(s):Laurent Chiche, MD, FEBVS | |
7:02 AM - 7:07 AM | 25 Years Of Robotic Vascular Surgery: If It is So good, Why Isn’t It Mainstream Now |
Presenter(s):Willem Wisselink, MD | |
7:08 AM - 7:13 AM | Focus On Radiation Protection During Simulation-Based Training Improves Both Correct Behavior And Procedural Performance: Proven By A Randomized Comparison |
Presenter(s):Lars B. Lonn, MD, PhD | |
7:14 AM - 7:19 AM | Inside Out: Next Generation Technology That Transmits Physical Intelligence And Parameters Continuously From Within The Patient: How Will It Help In Vascular Treatment |
Presenter(s):Barry T. Katzen, MD | |
RADIATION REDUCING IMAGING GUIDANCE TECHNIQUES | |
7:20 AM - 7:25 AM | True Radiation Reduction Strategies For Complex Endovascular Procedures: FORS, Digital Zooming, IVUS, And Live Fusion Guidance |
Presenter(s):Carlos H. Timaran, MD | |
7:26 AM - 7:31 AM | Updated Experience With The Fiberoptic 3D Endovascular Guidance With The Fiberoptic RealShape (FORS) System (From Philips): Advantages And Limitations |
Presenter(s):Joost van Herwaarden, MD, PhD | |
7:32 AM - 7:37 AM | Update On The 3D Radiation Free Electromagnetic Intraoperative Positioning System (IOPS) From Centerline For Endovascular Guidance: Advantages And Limitations |
Presenter(s):Matthew J. Eagleton, MD | |
7:38 AM - 7:44 AM | Panel Discussion |
END OF SESSION 9 | |
SESSION 10 SCHEDULE | |
Tuesday
SESSION 10:
NEW DEVELOPMENTS IN CAROTID DISEASE AND ITS TREATMENT; DIFFERING VIEWS ON TREATMENT OF ASYMPTOMATIC CAROTID STENOSIS (ACS) AND CAROTID SCREENING
Moderators:TBD
|
|
x | |
7:44 AM - 7:49 AM | Update On International Variations In Carotid Stenosis Treatment Within Countries And Between Countries Is Huge Despite All The RCTs On Which They Are Based Being The Same: What Are The Implications |
Presenter(s):Maarit Venermo, MD, PhD | |
7:50 AM - 7:55 AM | Current Optimal Treatment For Carotid Artery Dissection: When Best Medical Therapy (BMT), When Open Surgery, When Carotid Stenting (CAS) With Proximal Embolic Protection |
Presenter(s):Felice Pecoraro, MD | |
7:56 AM - 8:01 AM | Intracranial Imaging For Strokes With A Newly Developed Imaging Platform Using Artificial Intelligence To Integrate All Forms Of Imaging To Facilitate Patient Care: The VIZ.ai System |
Presenter(s):Allan L. Brook, MD | |
8:02 AM - 8:07 AM | Value Of Advanced Imaging In The Diagnosis And Treatment Of Near Total Occlusions And String Signs Of The Internal Carotid Artery (ICA): How Are They Best Treated: When Conservatively; When Invasively By CEA; By CAS |
Presenter(s):Christos D. Liapis, MD | |
8:08 AM - 8:13 AM | Update On Isolated Carotid Webs As A Cause Of Cryptogenic Stroke: How Best To Diagnose And Treat: How Should Asymptomatic Webs Be Treated |
Presenter(s):W. Charles Sternbergh III, MD / Clayton J. Brinster, MD | |
8:14 AM - 8:20 AM | Panel Discussion |
8:20 AM - 8:25 AM | DEBATE: ALL Asymptomatic Carotid Stenosis (ACS) Patients Are Best Treated Medically: Invasive Treatment Causes More Harm Than Good And Should Not Be Reimbursed |
Presenter(s):Anne L. Abbott, MD, PhD, FRACP | |
8:26 AM - 8:31 AM | DEBATE: Not So: About 25% Of ACS Patients Can Benefit From CEA Or CAS And Should Be So Treated And Reimbursed Accordingly |
Presenter(s):Bruce A. Perler, MD, MBA | |
8:32 AM - 8:37 AM | DEBATE: Both Views Are Wrong: Severe Carotid Stenosis Has Declined As A Cause Of Ischemic Stroke To <1% Per Year: So <5% Of ACS Patients Should Be Treated Invasively |
Presenter(s):Robert W. Chang, MD | |
8:38 AM - 8:43 AM | TBD |
DIFFERING VIEWS ON CAROTID SCREENING | |
8:44 AM - 8:49 AM | DEBATE: The Case For Widespread Carotid Screening To What End If ACS Should Not Be Treated |
Presenter(s):George S. Lavenson, MD | |
8:50 AM - 8:55 AM | DEBATE: The Case Against Carotid Screening: It Leads To Unneeded And Possibly Harmful Treatment |
Presenter(s):Anne L. Abbott, MD, PhD, FRACP | |
8:56 AM - 9:01 AM | Screening For ACS And Common Femoral Artery Disease: How Can It Guide Lipid Treatment: How Low Should LDL-Cholesterol (LDL-C) Be Pushed And What Will It Do To Carotid Plaques |
Presenter(s):Stavros K. Kakkos, MD, PhD / Andrew N. Nicolaides, MS, FRCS | |
9:02 AM - 9:07 AM | What Are The Effects Of A Minor Stroke With Apparent Full Recovery: Minor Strokes Are By No Means Minor: Why Is This Important In Evaluating The Conclusions Of RCTs |
Presenter(s):Emmanuel M. Houdart, MD | |
9:08 AM - 9:15 AM | Panel Discussion |
9:15 AM - 9:30 AM | Break – Visit Exhibits And Pavilions (2nd and 3rd Floors) |
END OF SESSION 10 | |
SESSION 11 SCHEDULE | |
Tuesday
SESSION 11:
MORE ABOUT CAROTID AND VERTEBRAL DISEASE: UPDATE ON INVASIVE TREATMENT FOR ACUTE STROKES
Moderators:TBD
|
|
x | |
9:30 AM - 9:35 AM | Carotid Artery Aneurysms: What Etiologies Cause Them; When Is Endovascular Treatment Best And Technical Tips For Doing So Successfully |
Presenter(s):Peter L. Faries, MD, FACS | |
9:36 AM - 9:41 AM | When After An Acute Stroke With Thrombolysis Treatment, Or Without, Should Carotid Endarterectomy (CEA) Be Performed: Delay Has Consequences: But CEA Within 48 Hours Of Symptom Onset Has A Higher Complication Rate |
Presenter(s):Maarit Venermo, MD, PhD | |
9:42 AM - 9:47 AM | After Thrombolysis And/Or Mechanical Thrombectomy For An Acute Stroke In Patients With Carotid Stenosis, Which Invasive Treatment (CEA Or CAS) Is Best And When Should It Be Performed |
Presenter(s):Laura Capoccia, MD, PhD | |
9:48 AM - 9:53 AM | With Acute Strokes, What Is New With Endovascular Intracranial Techniques For Arterial Clot Removal: How Can Artificial Intelligence (AI) And Intraarterial Thrombolysis With Alteplase (Genentech) Help – What Is Happening With The CHOICE RCT |
Presenter(s):L. Nelson Hopkins, MD / Adnan H. Siddiqui, MD, PhD | |
9:54 AM - 9:59 AM | How Does Temporal Access And A Through And Through Femoral Wire Facilitate CAS With A Difficult Aortic Arch: Technical Tips And Results |
Presenter(s):Piotr Myrcha, MD, PhD | |
10:00 AM - 10:05 AM | Acute Stroke Interventions: What Is New In 2023: Challenging Cases And Tips For Treating Them Successfully |
Presenter(s):Horst Sievert, MD | |
10:06 AM - 10:11 AM | How Best To Treat An ICA Occlusion With Distal Embolization: Sequence And Timing Of Treatment: Site Of Treatment (OR Versus Angio Suite Versus Hybrid Room): Technical Tips |
10:12 AM - 10:17 AM | Outcomes Of Carotid Interventions (CEA And CAS) In Women And Younger Patients: How And Why Do They Differ From Those In Men And Older Patients |
Presenter(s):Caron B. Rockman, MD | |
10:18 AM - 10:23 AM | Update On Endovascular Interventions In The Vertebro-Basilar System For Acute Strokes: A New Horizon, What Is Involved And Results |
Presenter(s):Ivo Petrov, MD, PhD | |
10:24 AM - 10:30 AM | Panel Discussion |
END OF SESSION 11 | |
SESSION 12 SCHEDULE | |
Tuesday
SESSION 12:
PROGRESS IN THE TREATMENT OF AORTIC AND AORTO-ILIAC OCCLUSIVE DISEASE
Moderators:TBD
|
|
x | |
10:30 AM - 10:35 AM | What Is New In The Treatment Of External Iliac Artery Endofibrosis In Committed Cyclists: Is There A Role For Endovascular Treatment |
Presenter(s):Kenneth J. Cherry, MD | |
10:36 AM - 10:41 AM | Hidden Tricks For Diagnosing Iliac Endofibrosis In Professional Cyclists: Diagnosis Can Be Challenging And Require Unusual Techniques |
Presenter(s):Gabriel Szendro, MD | |
10:42 AM - 10:47 AM | 5-Year Update On The Value Of VBX Balloon Expandable Covered Stents In Treating Complex Aorto-Iliac Occlusive Disease: Advantages And Limitations: When And How Does Shockwave Lithotripsy Help |
Presenter(s):Andrew Holden, MBChB | |
COVERED ENDOVASCULAR RECONSTRUCTION OF THE AORTIC BIFURCATION (CERAB) PROCEDURE | |
10:48 AM - 10:53 AM | Long-Term Outcomes Of The CERAB Procedure With Covered Stents For Complex Aorto-Iliac Occlusive Disease: Why It Is Better Than Kissing Bare Stents: Advantages Of The Gore VBX Balloon Expanded Covered Stent |
Presenter(s):Michel M.P. Reijnen, MD, PhD / Peter C.J. Goverde, MD | |
10:54 AM - 10:59 AM | The CERAB Technique: From A Niche Procedure To A Better General Solution For Complex Aorto-Iliac Occlusive Disease Based On The 2-Year Results Of The Multicenter BeGlory Registry |
Presenter(s):Maria A. Ruffino, MD, EBIR, FCIRSE | |
11:00 AM - 11:05 AM | TBD |
11:06 AM - 11:11 AM | Value Of Shockwave Intravascular Lithotripsy (IVL) For Calcified Aorto-Iliac Occlusive Disease Treatment And For Facilitating Large Bore Access With Narrowed Calcified Iliac Arteries |
Presenter(s):Daniel G. Clair, MD | |
11:12 AM - 11:18 AM | Panel Discussion |
11:18 AM - 11:23 AM | Impact Of Female Gender On Outcomes Of Endovascular Treatment Of Aorto-Iliac Occlusive Disease: When Is Open Repair Indicated |
Presenter(s):Franco Grego, MD | |
11:24 AM - 11:29 AM | Treatment Of Infrarenal And Pararenal Aortic Stenosis: When Stents; When Stent-Grafts; When Open Bypass: Why Results Are Worse In Women |
Presenter(s):Sigrid Nikol, MD | |
11:30 AM - 11:35 AM | Endovascular Treatment Of Aorto-Iliac Occlusions With Impotence (Leriche Syndrome): Long-Term Results: Is Open Repair Ever Needed |
Presenter(s):Sonia Ronchey, MD, PhD | |
11:36 AM - 11:41 AM | DEBATE: How To Treat Chronic Flush Juxtarenal Aortic Occlusions Endovascularly With Safety: Endo Is The Way To Go |
Presenter(s):David J. Minion, MD | |
11:42 AM - 11:47 AM | DEBATE: Not So: Open Or Hybrid Repairs Are Best For Complex Juxtarenal Aorto-Iliac Occlusive Disease: Technical Tips |
Presenter(s):Yamume Tshomba, MD | |
11:48 AM - 11:53 AM | TBD |
11:54 AM - 12:00 PM | Panel Discussion |
12:00 PM - 1:00 PM | Lunch Break – Visit Exhibits And Pavilions (2nd and 3rd Floors) |
END OF SESSION 12 | |
SESSION 13 SCHEDULE | |
Tuesday
SESSION 13:
NEW CONCEPTS, MACHINE LEARNING AND ARTIFICIAL INTELLIGENCE (AI) (See Also Session 87)
Moderators:TBD
|
|
x | |
1:00 PM - 1:05 PM | What Is Big Data In Vascular Surgery: How Can It Be Used With Artificial Intelligence (AI) In Evidence Based Medicine: How Can It Replace Randomized Controlled Trials (RCTs) |
Presenter(s):Jean-Baptiste Ricco, MD, PhD | |
1:06 PM - 1:11 PM | How Can AI Help In The Treatment Of Aorto-Iliac Occlusive Disease |
Presenter(s):Peter C.J. Goverde, MD | |
1:12 PM - 1:17 PM | Enhancing Clinical Decision Making In AAA Diagnosis And Treatment With AI: How Can It Help With Prediction Of AAA Growth, Endoleaks And Spinal Cord Ischemia |
Presenter(s):Kak Khee Yeung, MD, PhD | |
1:18 PM - 1:23 PM | Update On How Vascular Treatment Will Intersect With Other New Technologies: Wearable Trackers, AI, And Using CT Scans To Predict Plaque Histology (ElucidVivo) |
Presenter(s):David H. Deaton, MD, FACS | |
1:24 PM - 1:29 PM | How Does An AI Based Prediction Of Rupture Risk Compare With Size Based Predictions |
Presenter(s):Jes S. Lindholt, MD | |
1:30 PM - 1:35 PM | Is Image Fusion Guidance For Complex And Simple Aortic Procedures Really Worthwhile And Cost Effective: Why Is It A Question And Do We Need A Trial |
Presenter(s):Rachel E. Clough, PhD, FRCS | |
1:36 PM - 1:41 PM | How Can AI Facilitate Assessment After EVAR And F/B/EVAR: Are Volume Measurements Before And After Endo Repairs Necessary |
Presenter(s):Stephan Haulon, MD | |
1:42 PM - 1:47 PM | High Fidelity Computational Modeling To Help With Decision Making In Carotid Stenosis |
Presenter(s):Santi Trimarchi, MD, PhD | |
1:48 PM - 1:53 PM | Update On Siemens I-Flow: A New Intelligent Technology To Improve The Endo Treatment Of Lower Extremity Occlusive Disease |
Presenter(s):Ravi K. Veeraswamy, MD | |
1:54 PM - 1:59 PM | For The Novice, How In Simple Terms Do The FORS, IOPS And Cydar Guidance Systems Work To Improve Endovascular Procedures And Reduce Radiation Exposure |
Presenter(s):Mark A. Adelman, MD | |
2:00 PM - 2:05 PM | TBD |
2:06 PM - 2:12 PM | Panel Discussion |
END OF SESSION 13 | |
SESSION 14 SCHEDULE | |
Tuesday
SESSION 14:
PART 1: VASCULAR SURGERY’S NUMBERS AND IDENTITY AND HOW TO MEET THE SPECIALTY’S NEEDS FOR ITS SERVICES; THE IMPORTANCE OF MENTORSHIP IN VASCULAR SURGERY
PART 2: LATE BREAKING DEVELOPMENTS IN COVID RELATED VASCULAR DISEASE ISSUES
Moderators:TBD
|
|
x | |
PART 1 – Vascular Surgery’s Numbers And Identity And How To Meet The Specialty’s Needs For Its Services; The Importance Of Mentorship In Vascular Surgery | |
2:12 PM - 2:17 PM | What Makes Vascular Surgery Different, Are There Insufficient Numbers Of Vascular Trainees And Surgeons: How To Improve Our Identity And Recognition And Expand Our Numbers |
Presenter(s):Evan C. Lipsitz, MD, MBA | |
2:18 PM - 2:23 PM | Update On Applicants For 0+5 And 5+2 Vascular Surgery Training Programs: The Number Of Applicants Is Up: What About Their Quality: Do We Need More Programs |
Presenter(s):Peter L. Faries, MD, FACS / Dawn M. Coleman, MD | |
2:24 PM - 2:29 PM | Increased Diversity In Vascular Surgery And Will It Improve The Shortage Of Vascular Surgeons |
Presenter(s):Ruth L. Bush, MD, JD, MPH | |
2:30 PM - 2:35 PM | How To Improve Vascular Surgery Stature And Well-Being Within An Institution By Transforming It Into Its Own Free Standing Department: What Benefits Accrue |
Presenter(s):Jeffrey H. Hsu, MD | |
2:36 PM - 2:41 PM | Progress Made By The American Board Of Vascular Surgery (ABVS) In The Last Several Years: Do We Still Need An Independent Board And How Should We Achieve It |
Presenter(s):Alan M. Dietzek, MD, RPVI, FACS | |
2:42 PM - 2:47 PM | The Importance Of Mentorship In Vascular Surgery: How Best To Achieve It |
Presenter(s):Amy B. Reed, MD | |
2:48 PM - 2:53 PM | Panel Discussion |
PART 2 – Late Breaking Developments In COVID Related Vascular Disease Issues | |
2:54 PM - 2:59 PM | Current Developments In COVID-19 Prevention And Treatment: How Effective Are Current Vaccines, Boosters And Anti-Viral Therapies: What Is New And What Is In The Pipeline |
Presenter(s):Clayton J. Brinster, MD | |
3:00 PM - 3:05 PM | Timing Of A Major Operative Intervention After A Positive COVID-19 Test Affects Postoperative Mortality: When To Retest And When Best To Intervene |
Presenter(s):Panos Kougias, MD, MSc | |
3:06 PM - 3:11 PM | COVID-19 Associated Arterial Events Are Worse In No-Vaccinated Individuals: What Is Role And Effectiveness Of Endovascular Therapy |
Presenter(s):Michel Makaroun, MD | |
3:12 PM - 3:17 PM | Is The COVID-19 Pandemic Behind Us: What We Know About Herd Immunity And The Lasting Effects Of Long COVID |
Presenter(s):Clayton J. Brinster, MD | |
3:18 PM - 3:23 PM | Panel Discussion |
3:24 PM - 4:36 PM | Break – Visit Exhibits And Pavilions (2nd and 3rd Floors) |
END OF SESSION 14 | |
SESSION 15 SCHEDULE | |
Tuesday
SESSION 15:
PROGRESS IN THE TREATMENT OF VISCERAL AND RENAL ARTERY DISEASE
Moderators:TBD
|
|
x | |
3:36 PM - 3:41 PM | DEBATE: All Visceral And Renal Artery Aneurysms Can Be Treated Endovascularly: Bare Stent Flow Diverters Are The New Frontier In Their Treatment |
Presenter(s):Maria A. Ruffino, MD, EBIR, FCIRSE | |
3:42 PM - 3:47 PM | DEBATE: Open Treatment Of Visceral And Renal Artery Aneurysms Is Sometimes Best: When Is This So |
Presenter(s):Timur P. Sarac, MD | |
3:48 PM - 3:53 PM | Retrograde Open SMA Stenting (ROMS): It Is Indicated With Peritoneal Signs And When Prograde Stenting Is Not Possible: Tips To Gain Retrograde Access To The SMA |
Presenter(s):Richard J. Powell, MD | |
3:54 PM - 3:59 PM | With Acute Mesenteric Ischemia With Necrotic Bowel, Open Treatment With SMA Bypass Using A Deep Vein Conduit Is An Option |
Presenter(s):Patrick A. Stone, MD | |
4:00 PM - 4:05 PM | Technical Tips For Recanalizing Long Complex Visceral Artery (SMA) Occlusions |
Presenter(s):Armando Mansilha, MD, PhD, FEBVS | |
4:06 PM - 4:11 PM | Update On The New SVS Practice Guidelines For Treating Visceral Artery Aneurysms; When Endo; When Open |
Presenter(s):Rabih A. Chaer, MD | |
4:12 PM - 4:17 PM | Optimal Current Treatment Of Renal Artery Aneurysms: When Endo; When Open; Technical Tips |
Presenter(s):Fred A. Weaver, MD, MMM | |
4:18 PM - 4:23 PM | The Vascular Low Frequency Consortium: What Is It And What Management Changing Information Does It Tell Us About The Size When Renal Artery Aneurysms Become Dangerous: It Is >3 cm In Diameter |
Presenter(s):Peter F. Lawrence, MD | |
4:24 PM - 4:29 PM | Best Endovascular Techniques To Exclude Large Renal And Visceral Aneurysms |
Presenter(s):Jacques Busquet, MD | |
4:30 PM - 4:36 PM | Panel Discussion |
END OF SESSION 15 | |
SESSION 16 SCHEDULE | |
Tuesday
SESSION 16:
UPDATE ON OPEN VASCULAR SURGICAL AND HYBRID PROCEDURES; PROGRESS IN THE TREATMENT OF AORTIC COARCTATIONS
Moderators:TBD
|
|
x | |
4:36 PM - 4:41 PM | Open Conversion For Failing Suprarenal And Thoracic Endovascular Repairs: When Is Endo Rescue Not Possible And Open Conversion Necessary: Technical Tips |
Presenter(s):Francis J. Caputo, MD | |
4:42 PM - 4:47 PM | When Is Open Treatment Of Complex Aorto-Iliac Occlusive Disease Best: Tips And Tricks For Doing It Safely In The Endovascular Era |
Presenter(s):Timur P. Sarac, MD | |
4:48 PM - 4:53 PM | Technical Tips For Open Retroperitoneal Exposure Of The Aorta And All Its Abdominal Branches; How To Do A Retroperitoneal Aorto- Bifemoral Bypass |
Presenter(s):Kamphol Laohapensang, MD | |
4:54 PM - 4:59 PM | Use Of Minimal Incisions For Retroperitoneal Aorto-Bifemoral Bypass And Other Procedures: Technical Tips And Limitations |
Presenter(s):Robert M. Proczka, MD, PhD | |
5:00 PM - 5:05 PM | Duplex Surveillance Should Be Used After All Open Aorto-Bifemoral Bypasses: How Does It Improve Outcomes |
Presenter(s):Keith D. Calligaro, MD | |
5:06 PM - 5:11 PM | Open Treatment Of Infected Aortic Grafts And Endografts By Replacing Them With Rifampkin Soaked Dacron Grafts: When Is It Appropriate And Results |
Presenter(s):Manju Kalra, MBBS | |
5:12 PM - 5:17 PM | Update On Renal Consequences Of Left Renal Vein Division During Open AAA Repair: It Is Not Always Benign |
Presenter(s):Kimihiro Komori, MD, PhD | |
5:18 PM - 5:23 PM | Open And Endovascular Treatment Of Visceral, Renal And Lumbar Artery Aneurysms In Children: When Is Open Treatment indicated; When Endovascular |
Presenter(s):James C. Stanley, MD | |
5:24 PM - 5:30 PM | Panel Discussion |
UPDATE ON COARCTATION TREATMENT | |
5:30 PM - 5:35 PM | Endovascular Repair Of Aortic Coarctation: Balloon Angioplasty Versus Bare Stents Versus Covered Stents: When Is Open Repair Necessary |
Presenter(s):Tilo Koelbel, MD, PhD | |
5:36 PM - 5:41 PM | Update On The Experience With BeGrafts (From Bentley), A Balloon Expandable Covered Stent For Treating Aortic Coarctations: Advantages And Limitations |
Presenter(s):Elchanan Bruckheimer, MBBS | |
5:42 PM - 5:47 PM | Positive Remodeling In The Ascending Aorta As Well As Distally After TEVAR Treatment Of Aortic Coarctations |
Presenter(s):Frank R. Arko, MD | |
5:48 PM - 5:53 PM | Axillo-Unifemoral And Axillo-Bifemoral Bypasses Have Equal Patency For More Than A Year: Why The Bilateral Procedure Should Only Be Used When Bilateral Ischemia Exists |
Presenter(s):Jeffrey J. Siracuse, MD, MBA, FACS | |
5:54 PM - 5:59 PM | Panel Discussion End of Program B |
END OF SESSION 16 | |
SESSION 17 SCHEDULE | |
Tuesday
SESSION 17:
MANAGEMENT OF PULMONARY EMBOLISM: THE ULTIMATE APPROACH – PART 1
Moderators:Michael R. Jaff, DO
|
|
x | |
END OF SESSION 17 | |
SESSION 18 SCHEDULE | |
Tuesday
SESSION 18:
MANAGEMENT OF PULMONARY EMBOLISM: THE ULTIMATE APPROACH – PART 2
Moderators:Michael R. Jaff, DO
|
|
x | |
END OF SESSION 18 | |
SESSION 19 SCHEDULE | |
Tuesday
SESSION 19:
HOT NEW TOPICS RELATED TO LOWER EXTREMITY OCCLUSIVE DISEASE AND ITS TREATMENTS
Moderators:TBD
|
|
x | |
1:00 PM - 1:05 PM | Key Points From The SVS Appropriate Use Criteria For Management Of Intermittent Claudication: Are Invasive Treatments Being Overused And Will These Criteria Help |
Presenter(s):Jessica P. Simons, MD, MPH / Karen Woo, MD, PhD | |
1:06 PM - 1:11 PM | What Are The Dangers Of Working In An Office Based Lab (OBL): Why I Chose Not To Work There |
Presenter(s):Dipankar Mukherjee, MD | |
1:12 PM - 1:17 PM | Real Five-Year Single Center Results With Atherectomy For De Novo Lower Extremity Lesions And In Stent Restenosis: How Good Or Bad Are They |
Presenter(s):Russell H. Samson, MD, DFSVS, RVT, FACS | |
1:18 PM - 1:23 PM | Intravascular Lithotripsy (From Shockwave) For Peripheral Arterial Occlusive Lesions: What Are The New Systems (Mini And M5+) For Delivering And What Are The Advantages |
Presenter(s):Andrew Holden, MBChB | |
1:24 PM - 1:29 PM | How Do SoundBite Wires (From SoundBite Medical) Help To Cross Calcified Lesions, Especially BTK: Updated Experience |
Presenter(s):Marianne Brodmann, MD | |
1:30 PM - 1:35 PM | Alternate Anatomic Approaches To Lower Extremity Arteries When Standard Approaches Are Prevented By Scarring Or Infection |
Presenter(s):Ramesh K. Tripathi, MD, FRCS, FRACS | |
1:36 PM - 1:41 PM | Updated Status And Prospects For Sirolimus Coated Devices And Bioresorbable Stents ATK And BTK |
Presenter(s):Marianne Brodmann, MD | |
1:42 PM - 1:47 PM | Advances In Deep Venous Arterialization Techniques: Better Access, Procedure Maintenance And Wound Care Matter For Limb Salvage In No Option CLTI Patients |
Presenter(s):Anahita Dua, MD, MS, MBA | |
1:48 PM - 2:04 PM | Panel Discussion |
END OF SESSION 19 | |
SESSION 20 SCHEDULE | |
Tuesday
SESSION 20:
MORE HOT NEW TOPICS RELATED TO LOWER EXTREMITY OCCLUSIVE DISEASE AND ITS TREATMENT
Moderators:TBD
|
|
x | |
2:04 PM - 2:09 PM | How To Train Vascular Surgeons In Distal Bypass Procedures In 2023: How Many Cases Are Needed To Achieve Competence |
Presenter(s):Francesco Spinelli, MD | |
2:10 PM - 2:15 PM | Novel Uses Of Selective Superficial Venous Arterialization To Achieve Lower Limb Salvage: Techniques, Indications, Precautions And Results |
Presenter(s):John M. Felder, MD / Patrick J. Geraghty, MD | |
2:16 PM - 2:21 PM | Coagulation Testing To Allow Optimal Thromboprophylaxisis And Decrease Thrombosis Rates In Lower Extremity Grafts And Stents |
Presenter(s):Anahita Dua, MD, MS, MBA | |
2:22 PM - 2:27 PM | Fraction Flow Reserve (FFR) In Claudicants And CLTI Patients: The Value Of Physiology Over Anatomy In The Fempop Segment |
Presenter(s):Konstantinos Katsanos, MSc, MD, PhD, EBIR | |
2:28 PM - 2:33 PM | Pedal Acceleration Time (PAT): What Is It And Its Feasibility And Utility As An Assessment Tool For Limb Ischemia And Adequacy Of Revascularization Procedures |
Presenter(s):Vincent L. Rowe, MD | |
2:34 PM - 2:39 PM | What Are The Best Ways To Evaluate CLTI Treatment Outcomes: Physiology (ABIs And PVRs), Wound Healing, Anatomy (Angiography Or Ultrasound), MACE Or MALE: Why It Matters |
Presenter(s):Ido Weinberg, MD, MSc / Mitchell D. Weinberg, MD | |
2:40 PM - 2:45 PM | Head To Head Comparison Of The SUPERA Interwoven Stent And Drug Eluting Stents For The Treatment Of Femoropopliteal Lesions: Advantages, Disadvantages And Specific Indications For Each |
Presenter(s):Iris Baumgartner, MD | |
2:46 PM - 2:52 PM | Panel Discussion |
2:52 PM - 3:00 PM | Break – Visit Exhibits And Pavilions (2nd and 3rd Floors) |
END OF SESSION 20 | |
SESSION 21 SCHEDULE | |
Tuesday
SESSION 21:
HOT NEW TOPICS RELATED TO LOWER EXTREMITY OCCLUSIVE DISEASE
Moderators:TBD
|
|
x | |
3:00 PM - 3:05 PM | Pillars For Success With Radial Artery Access For Remote Visceral, Renal Or Lower Extremity Lesion Treatment |
Presenter(s):Marcelo Guimaraes, MD, MBA, FSIR | |
3:06 PM - 3:11 PM | Value And Technical Tips To Make The Supera Stent Work In Curved And Angulated Non-SFA Lesion Locations |
Presenter(s):Rajiv Parakh, MBBS, MS, FRCS | |
3:12 PM - 3:17 PM | Non-Aspiration Based Mechanical Thrombo-Embolectomy With The Pounce (From Surmodics) Or Rotarex (From BD) Devices: How Do They Work And What Will Their Role Be In Treating Acute Limb Ischemia |
Presenter(s):Gary M. Ansel, MD | |
3:18 PM - 3:23 PM | Pedal Bypass As A Bail Out After Failed Or Compromised Retrograde Access: Rescuing A Threatened Limb After Bridges Burned |
Presenter(s):Palma M. Shaw, MD, MBA, FACS, RPVI, DFSVS | |
3:24 PM - 3:29 PM | Technical Tips For A Successful BTK Intervention In Patients With CLTI Including How To Perform An Antegrade Femoral Artery Puncture And Pass The Guidewire Into The SFA |
Presenter(s):Ali Amin, MD, RVT, FACS, FACC | |
3:30 PM - 3:35 PM | Importance Of Technical Factors In Use Of Drug Coated Balloons (DCBs): Value Of IVUS And DCB Undersizing: Are There Differences With Chronic Total Occlusions (CTOs) |
Presenter(s):Jihad A. Mustapha, MD | |
3:36 PM - 3:41 PM | Local Anesthetic Injection Into Lesion Site Facilitates PTA And Stent Placement: How To Do It (Video Presentation) |
Presenter(s):Andrej Schmidt, MD | |
3:42 PM - 3:47 PM | Panel Discussion |
3:47 PM - 3:52 PM | Does Atherectomy Still Have Value After Shockwave Lithotripsy Treatment Of A Calcified Occlusive Lesion |
Presenter(s):Lawrence A. Garcia, MD | |
3:53 PM - 3:58 PM | When Should Common Femoral Occlusive Disease Be Treated Endovascularly Based On The CONFESS Trial |
Presenter(s):Hany M. Zayed, MD | |
3:59 PM - 4:04 PM | The Deeper Limus Trial Using A Limus Coated Temporary Spur Balloon (From Reflow Medical): How Does The Device Work And Preliminary Results |
Presenter(s):Marianne Brodmann, MD | |
4:05 PM - 4:10 PM | Heel Ulceration And Ischemic Gangrene Involving The Achilles Tendon Should Not Be An Indication For A BTK Amputation: Revascularization And Appropriate Local Treatment Can Save Such A Limb |
Presenter(s):Mark G. Davies, MD | |
4:11 PM - 4:16 PM | Popliteal Artery-To-Distal Bypass For Limb Salvage; Status In 2023: Technical Tips And Value: When Is It Better Than Endovascular Treatments |
Presenter(s):Francesco Spinelli, MD | |
4:17 PM - 4:23 PM | Panel Discussion |
END OF SESSION 21 | |
SESSION 22 SCHEDULE | |
Tuesday
SESSION 22:
MORE HOT NEW TOPICS RELATED TO LOWER EXTREMITY OCCLUSIVE DISEASE AND CHRONIC LIMB THREATENING ISCHEMIA (CLTI)
Moderators:TBD
|
|
x | |
4:24 PM - 4:29 PM | CLTI Is A Global Epidemic; How Can A CLTI Program Decrease Its Morbidity |
Presenter(s):Barry T. Katzen, MD | |
4:30 PM - 4:35 PM | Open And Endo Revascularization In Young Patients With PAD: What Works, What Doesn’t, What Factors Impact Outcomes And How Should Treatment Be Modified |
Presenter(s):William P. Robinson, MD | |
4:36 PM - 4:41 PM | Is BEST-CLI Best For CLI Patients And Interventional Treatments |
Presenter(s):Lawrence A. Garcia, MD | |
4:42 PM - 4:47 PM | Intravascular Lithotripsy And DCB Versus DCB Alone In The Treatment Of Infrapopliteal Lesions In Diabetics: Rationale And Design Of The DEBATE-BTK SHOCK RCT And Early Results |
Presenter(s):Francesco Liistro, MD | |
4:48 PM - 4:53 PM | How To Size Lower Extremity Target Arteries For Endo Treatments Accurately Using Intravascular Ultrasound (IVUS): How Does It Help |
Presenter(s):Jos C. van den Berg, MD, PhD | |
4:54 PM - 4:59 PM | Lower Extremity Interventions (PTA, Stents, Atherectomy) Under IVUS Guidance: Its Costs, Advantages And Limitations |
Presenter(s):Ignacio Escotto, MD | |
5:00 PM - 5:06 PM | Panel Discussion |
5:06 PM - 5:11 PM | Drug-Coated Versus Uncoated PTA Balloons For The Treatment Of Infrapopliteal Occlusive Lesions: A Systematic Review And Meta-Analysis Of Randomized Controlled Trials: When Infrapopliteal DCBs, When Infrapopliteal DESs |
Presenter(s):Jihad A. Mustapha, MD | |
5:12 PM - 5:17 PM | Experience With >1500 Retrograde Canalization For Chronic Total Occlusions (CTOs); What Predicts Technical Success And What Predicts Periprocedural Complications: Are Reentry Devices Ever Helpful |
Presenter(s):Erwin Blessing, MD | |
5:18 PM - 5:23 PM | How To Avoid Or Manage Unexpected Catastrophes When Treating CLTI In The Operating Room Or Angio Suite |
Presenter(s):Robert B. McLafferty, MD, MBA | |
5:24 PM - 5:29 PM | Tibial Interventions For Intermittent Claudication: An Ethical And Professional Challenge For All Vascular Specialists And The Vascular Community |
Presenter(s):Michael S. Conte, MD | |
5:30 PM - 5:35 PM | A New Technology (From AOTI) Combining Local Oxygen Therapy With Cycled Compression And Humidification Enhances Healing Of Diabetic Wounds And Ischemic Ulcers After Revascularization |
Presenter(s):Anil P. Hingorani, MD / Enrico Ascher, MD | |
5:36 PM - 5:41 PM | Contemporary Comparative Results Of BTK Open Bypass Revascularization: Heparin Bonded PTFE Grafts Versus In Situ Or Reversed Vein Grafts: When Are PTFE Grafts To Tibial/Peroneal Arteries Worthwhile |
Presenter(s):Carlo Pratesi, MD / Giovanni Pratesi, MD | |
5:42 PM - 5:47 PM | Distal Bypasses Under Nerve Block Without General Anesthesia Improves Results Of Bypasses For CLTI |
Presenter(s):Nobuyoshi Azuma, MD | |
5:48 PM - 5:53 PM | Techniques For Overcoming Problems With Subintimal Angioplasty For Chronic Total Occlusions (CTOs): Like Inability To Re-Enter The True Lumen: Fancy Gadgets (Outback, Pioneer, Enteer, OffRoad) Are Almost Never Needed |
Presenter(s):Ali Amin, MD, RVT, FACS, FACC | |
5:54 PM - 5:59 PM | How To Do Bypass Surgery To Heavily Non-Compressible Calcified Target Arteries |
Presenter(s):Enrico Ascher, MD / Frank J. Veith, MD | |
6:00 PM - 6:06 PM | Panel Discussion End of Program C-2 |
END OF SESSION 22 | |
SESSION 40 SCHEDULE | |
Tuesday
SESSION 40:
MORE ADVANCES RELATED TO TREATING PATHOLOGY INVOLVING THE ASCENDING AORTA AND THE AORTIC ARCH; AORTIC DISSECTIONS AND THEIR TREATMENT
Moderators:TBD
|
|
x | |
8:00 AM - 8:05 AM | When In Addition To TEVAR And F/BEVAR Are False Lumen (FL) Occlusion Procedures Needed To Reduce FL Pressure And Promote Aortic Remodeling |
Presenter(s):Götz M. Richter, MD, PhD | |
8:06 AM - 8:11 AM | With TAAD When And How Should The Distal Aorta Be Treated By TEVAR Before Repairing The Ascending Aorta |
Presenter(s):Ourania Preventza, MD / Joseph S. Coselli, MD | |
8:12 AM - 8:17 AM | Current Status Of A Catheter Aortic Septotomy Device For Treating Aortic Dissections: Why And How Should It Work As A Treatment |
Presenter(s):Ramon Berguer, MD, PhD / Juan C. Parodi, MD | |
8:18 AM - 8:23 AM | With Chronic TBADs Laser Assisted Resection Of The Dissection Membrane Creates A Single Lumen TEVAR Landing Zone: How Is The Technique Performed And Early Results |
Presenter(s):Bjőrn Sonesson, MD, PhD | |
8:24 AM - 8:29 AM | Continuing Experience For Precise TEVAR Placement In Or Near The Arch By Valsalva And PEEP (Munich Valsalva Maneuver): It Is Safe And Effective And Better Than Adenosine, Rapid Pacing And Caval Occlusion: How To Do It And Results |
Presenter(s):Nikolaos Tsilimparis, MD, PhD | |
8:30 AM - 8:35 AM | Panel Discussion |
8:35 AM - 8:40 AM | Single, Double Or 3-Branched Endograft Devices For Arch Lesion Repairs: When Is Each Best And Why: How To Do It From A Totally Femoral Approach |
Presenter(s):Gustavo S. Oderich, MD FACS | |
8:41 AM - 8:46 AM | An Off-The-Shelf Combined Valve+Fenestrated Endograft For Treating Acute TAADs – An Endo Bentall: Device Description, Indications And Clinical Status |
Presenter(s):Stephan Haulon, MD | |
8:47 AM - 8:52 AM | Percutaneous Endovascular Arch Repair Is Feasible With The Use Of Adjuncts: The “Innominate Approach” Avoids The Need To Get Open Exposure Of The Carotid Arteries For Access: How Is It Done |
Presenter(s):Timothy A. Resch, MD, PhD | |
8:53 AM - 8:58 AM | Physician Modified Double Fenestrated Stent-Grafts (PMEGS) For Total Aortic Arch Repair: Technique, Precautions And Results In 150 Cases |
Presenter(s):Ludovic Canaud, MD, PhD | |
8:59 AM - 9:04 AM | Zone 0 Aortic Arch Branched Endograft Repair Is Feasible With A Mechanical Aortic Valve: Tips An Tricks For Performing It Without Impairing Valve Function |
Presenter(s):Nikolaos Tsilimparis, MD, PhD | |
9:05 AM - 9:11 AM | Panel Discussion |
9:11 AM - 9:24 AM | Break – Visit Exhibits And Pavilions (2nd and 3rd Floors) |
END OF SESSION 40 | |
Wednesday, November 15, 2023
Print Entire 2023 Program:
![]() |
|
SESSION 23 SCHEDULE | |
Wednesday
SESSION 23:
GENERALITIES IN THE ENDOVASCULAR AND OPEN TREATMENT OF LOWER EXTREMITY OCCLUSIVE DISEASE AND CLTI
Moderators:TBD
|
|
x | |
6:40 AM - 6:45 AM | How Do Prior Endovascular Interventions Affect Future Lower Extremity Bypass Outcomes For CLTI: Why Do The Results Of The BEST-CLI Trial Make This More Important |
Presenter(s):Ramesh K. Tripathi, MD, FRCS, FRACS | |
6:46 AM - 6:51 AM | Do Diabetic Patients With CLTI And Extensive Foot Necrosis Have Time For An Endovascular First Strategy: Primary Open Bypass Is Better Treatment In This Setting |
Presenter(s):Katariina M. Noronen, MD, PhD | |
6:52 AM - 6:57 AM | Presenting Symptoms Of Lower Extremity Occlusive Disease And Intermittent Claudication Are Different In Women Than In Men: Why Is This Important |
Presenter(s):Linda M. Harris, MD | |
6:58 AM - 7:03 AM | Selective Coronary Revascularization Based On Preop CT Fractional Flow Reserve (FFRCT) Improves 3-Year Survival Of CLTI Patients After Lower Extremity Revascularization (Endo And Open): When Should The Coronary Revascularization Be Performed – Before Or After The Lower Extremity Procedure: Are There Other Precautions – Value Of Troponin Testing |
Presenter(s):Christopher K. Zarins, MD / Dainis K. Krievins, MD | |
7:04 AM - 7:09 AM | Why Does Medial Artery Calcification (MAC) Lead To Small Artery disease (SAD): A Computational Based Analysis Of Lower Limb Blood Flow Reveals That Increasing Vascular Stiffness May Be Causative: Can Anything Be Done About It |
Presenter(s):Roberto Ferraresi, MD | |
OPTIMAL TECHNIQUES FOR VESSEL PREP FOR ENDOVASCULAR TREATMENTS | |
7:10 AM - 7:15 AM | Optimal Different Techniques Of Vessel Prep For Plain Old Balloon Angioplasty (POBA), Drug Coated Balloon (DCB) Treatment And Drug Eluting Stent (DES) Treatment |
Presenter(s):Fabrizio Fanelli, MD, EBIR | |
7:16 AM - 7:21 AM | Technical Tips For Vessel Prep For DCBs And DESs: It Is Different And Not Simple: Is Vessel Prep Currently Overrated |
Presenter(s):Erwin Blessing, MD | |
7:22 AM - 7:27 AM | New Devices And A New Paradigm For Treating Lower Extremity Arterial Lesions Via A Radial Approach: Can Lesions Below The Knee Be Treated |
Presenter(s):Craig M. Walker, MD | |
7:28 AM - 7:33 AM | What Are The Downsides To Trans-Radial Or Pedal Access |
Presenter(s):Gary M. Ansel, MD | |
TECHNICAL TIPS ON GUIDEWIRE CHOICE AND USAGE | |
7:34 AM - 7:39 AM | Tips For Treating Difficult BTK/BTA Lesions: How To Get A Guidewire Across A Long Calcified Occlusion, Getting A Resistant Balloon To Go Over The Wire And Tips For Retrograde Access |
Presenter(s):Marco G. Manzi, MD | |
7:40 AM - 7:45 AM | Guidewire Tips For Treating Lesions Below The Ankle (BTA): Sliding, Piercing, Dissecting, Retrograde Maneuvers |
Presenter(s):Roberto Ferraresi, MD | |
7:46 AM - 7:53 AM | Panel Discussion |
END OF SESSION 23 | |
SESSION 24 SCHEDULE | |
Wednesday
SESSION 24:
NEW DEVELOPMENTS IN ATHERECTOMY, STENTS (UNCOATED, COATED AND BIORESORBABLE)
Moderators:TBD
|
|
x | |
PROGRESS IN ATHERECTOMY | |
7:53 AM - 7:58 AM | New Developments In Laser Atherectomy And Lithotripsy: What Progress Has Been Made And Are Their Benefits Proven |
Presenter(s):George L. Adams, MD | |
7:59 AM - 8:04 AM | Which Vascular Specialists Are Performing Tibial Atherectomies And Angioplasties For Intermittent Claudication And Are There Suboptimal Outcomes |
Presenter(s):Caitlin W. Hicks, MD, MS | |
8:05 AM - 8:10 AM | Update On Optical Coherence Tomography (OCT) Guided Intraluminal Crossing And Atherectomy (Pantheris) For Long Total SFA Occlusions: Superiority Over Other Techniques That Use Subintimal Crossing |
Presenter(s):Todd R. Vogel, MD, MPH | |
8:11 AM - 8:16 AM | 2-Year Experience With The Rotarex Atherectomy And Thrombectomy System (From BD) For Arterial Occlusive Disease And In Stent Restenosis (ISR): How Does It Work And Advantages |
Presenter(s):Michael K.W. Lichtenberg, MD | |
UPDATE ON THE SUPERA STENT | |
8:17 AM - 8:23 AM | Update On The Advantages Of The Supera Vasculomimetic (VMI) Stent For Treating Long Complex Fempop Occlusive Lesions: Is There Value To DCB Vessel Prep First |
Presenter(s):Peter C.J. Goverde, MD | |
8:23 AM - 8:28 AM | Update On The Supera Interwoven Stent: When Is It The Best Treatment And How To Optimally Deploy This Unique Stent |
Presenter(s):D. Christopher Metzger, MD / Craig M. Walker, MD | |
DRUG ELUTING STENTS (DESs) FOR BTK LESIONS | |
8:29 AM - 8:34 AM | Updated Experience With Everolimus And Other Nonabsorbable DESs To Treat Infrapopliteal BTK Lesions – Long And Short - Causing CLTI: What Are The Stents And How Are They Doing |
Presenter(s):Robert A. Lookstein, MD, MHCDL, FSIR, FAHA | |
8:35 AM - 8:40 AM | Update On Bioresorbable Everolimus DESs To Treat BTK Lesions Causing CLTI: Promising Results Up To 5 Years: From The DISAPEAR Registry And A Meta-Analysis Of Other Bioresorbable BTK Stent Results |
Presenter(s):Steven Kum, MD / Ramon L. Varcoe, MBBS, MS, FRACS, PhD, MMed (ClinEpi) | |
8:41 AM - 8:46 AM | Progress In And Early Results Of The LIFE-BTK Randomized Controlled Comparison Of Abbott’s Esprit Drug-Eluting Resorbable Stent With Plain Balloon Angioplasty (POBA) |
Presenter(s):Ramon L. Varcoe, MBBS, MS, FRACS, PhD, MMed (ClinEpi) / Sahil A. Parikh, MD / Brian G. DeRubertis, MD | |
8:47 AM - 8:52 AM | Updated Results With A 3-French Compatible Microstent (From Micro Medical) For Antegrade Or Retrograde Insertion To Treat Tibial Artery Lesions: From The STAND RCT And The HEAL Registry |
Presenter(s):Robert E. Beasley, MD, FSIR, FSCAI / Marco G. Manzi, MD | |
8:53 AM - 9:00 AM | Panel Discussion |
END OF SESSION 24 | |
SESSION 25 SCHEDULE | |
Wednesday
SESSION 25:
LOWER EXTREMITY TOPICS RELATED TO DRUG COATED BALLOONS (DCBs) AND DRUG ELUTING STENTS (DESs)
Moderators:TBD
|
|
x | |
9:00 AM - 9:05 AM | Older And More Recent Meta-Analyses Reveal Increased Mortality And Amputation Rates In Patients Receiving Paclitaxel Coated Devices Compared To Uncoated Devices: Are These Increased Rates Still Valid In View Of The Many Recent Studies That Do Not Confirm Them |
Presenter(s):Konstantinos Katsanos, MSc, MD, PhD, EBIR | |
9:06 AM - 9:11 AM | Large Population Based German Multicenter Study Of Paclitaxel Coated BTK DCBs And DESs Indicates Decreased Mortality And Amputation Rates Compared To Uncoated Devices |
Presenter(s):Christian A. Behrendt, MD | |
9:12 AM - 9:17 AM | The Final Word On The Safety Of Paclitaxel Coated Balloons And Stents: Putting Together Observation, Randomized Trial And Meta-Analysis Derived Data |
Presenter(s):Eric A. Secemsky, MD, MSc | |
9:18 AM - 9:23 AM | 2-Year Results With The Sundance DCB (Surmodics) To Treat BTK Occlusive Lesions: From The Swing Trial |
Presenter(s):Ramon L. Varcoe, MBBS, MS, FRACS, PhD, MMed (ClinEpi) | |
9:24 AM - 9:29 AM | Update On DCBs For BTK Angioplasty: RCT Comparing A Paclitaxel DCB (Litos From Acotec) Versus A Sirolimus DCB (Magic Touch From Concept Medical): 6-Month Results from the DEBATE BTK DUELL RCT |
Presenter(s):Francesco Liistro, MD | |
9:30 AM - 9:35 AM | Progress With A Sustained Release Sirolimus DCB: Results With The Magic Touch DCB Compared To A Paclitaxel DCB: From The SIRONA Study |
Presenter(s):Thomas Zeller, MD / Andrej Schmidt, MD / Dierk Scheinert, MD / Marianne Brodmann, MD | |
9:36 AM - 9:41 AM | Advential Drug Delivery With The BullFrog Device (From Mercator Medical) And The Spur Device (From ReFlow): How Do They Work And How Will We Know They Improve Results |
Presenter(s):William A. Gray, MD | |
9:42 AM - 9:47 AM | The Light And Darkness Of Fluoropolymer-Based Limus DESs In The Treatment Of Femoropopliteal Lesions |
Presenter(s):Osamu Iida, MD | |
9:48 AM - 9:53 AM | TBD |
9:54 AM - 9:59 AM | Are DESs Ever Associated With Aneurysmal Degeneration: Is It Related To The Drug (Paclitaxel Or Limus) Or To The Fluoropolymer Excipient To Which The Drug Is Attached) |
Presenter(s):Osamu Iida, MD | |
10:00 AM - 10:08 AM | Panel Discussion |
10:08 AM - 10:18 AM | Break – Visit Exhibits And Pavilions (2nd and 3rd Floors) |
END OF SESSION 25 | |
SESSION 26 SCHEDULE | |
Wednesday
SESSION 26:
NEW DEVELOPMENTS IN DRUG COATED BALLOONS (DCBs) AND DRUG ELUTING STENTS (DESs): UPDATES ON RANDOMIZED CONTROLLED TRIALS (RCTs) AND BTK LESION TREATMENTS WITH DCBs AND DESs
Moderators:TBD
|
|
x | |
NEW INFORMATION ON DCBs AND DESs FOR FEMPOP LESIONS: UPDATES ON RCTs | |
10:18 AM - 10:23 AM | DCB Treatment Of Femoropopliteal Lesions Causing CLTI (From Boston Scientific) Is Cost Effective: Based On A 2-Year Study Of Patients Treated With Ranger DCBs: Advantages Of An .018 Device Often Suitable For Radial Access |
Presenter(s):Ignacio Escotto, MD | |
10:24 AM - 10:29 AM | Stellarex (Philips) DCBs With Low Dose Paclitaxel Is Safe And Has Higher Patency Rates Than POBA With De Novo Or Recurrent Fempop Lesions At 5 Years In The ILLUMENATE US And European RCTs |
Presenter(s):Sean P. Lyden, MD / Marianne Brodmann, MD / Sahil A. Parikh, MD / William A. Gray, MD | |
10:30 AM - 10:35 AM | 2-Year Results Of A RCT Comparing SurVeil DCBs (Surmodics) With In.Pact DCBs For Treating Fempop Lesions: From the TRANSCEND Trial |
Presenter(s):Peter A. Schneider, MD | |
10:36 AM - 10:41 AM | New Findings From The DRASTICO Study Comparing DESs To DCBs For Fempop Lesions: 5-Year Results With TASC A/B Lesions Versus TASC C/D Lesions |
Presenter(s):Francesco Liistro, MD | |
10:42 AM - 10:47 AM | Value Of In.Pact DCBs For Long Complex SFA-Pop Lesions Including ISR And CTOs: Technical Tips And Contraindications: From The Global Registry: What Is The Best Endo Treatment For These Lesions |
Presenter(s):Gunnar Tepe, MD / Marianne Brodmann, MD | |
10:48 AM - 10:53 AM | Update On The Randomized Head To Head Comparison Of In.Pact (Medtronic) And Ranger (Boston Scientific) DCBs For Complex SFA Lesions: 3-Year Results Of The COMPARE RCT: Similar Results With Different Paclitaxel Dosages |
Presenter(s):Dierk Scheinert, MD / Sabine Steiner, MD | |
10:54 AM - 10:59 AM | Below The Ankle Endo Interventions In 2023: Techniques, Devices And Should Balloons Be Drug Coated Or Not |
Presenter(s):Marianne Brodmann, MD | |
11:00 AM - 11:05 AM | New Information On The Safety And Effectiveness Of The Cook Zilver PTX DES Based On An Updated Meta-Analysis And Global Data: When Is It The Best DES; When Is It The Best Treatment: Is Distal Microembolization A Concern |
Presenter(s):Peter A. Schneider, MD / William A. Gray, MD / Sahil A. Parikh, MD / Michael D. Dake, MD | |
11:06 AM - 11:11 AM | Updated 4-Year Results Of The IMPERIAL RCT Head To Head Comparison Of The Eluvia DES (Boston Scientific) With The Zilver PTX DES (Cook): Both Are Safe And Effective: Is There A Difference |
Presenter(s):Stefan Mueller-Huelsbeck, MD / William A. Gray, MD / Thomas Zeller, MD | |
11:12 AM - 11:18 AM | Panel Discussion |
NEW INFORMATION ON BTK DCBs AND DESs | |
11:18 AM - 11:23 AM | Advances In BTK Drug Delivery Technology And DCBs: What Have We Learned From The In.Pact Deep BTK DCB Trial And New Challenges With Treating CLTI Patients |
Presenter(s):Thomas Zeller, MD | |
11:24 AM - 11:29 AM | 4-Year Results From The AcoArt II BTK DCB RCT Show Safety With No Increased Mortality And Improved Patency Versus POBA To Treat BTK Lesions |
Presenter(s):Wei Guo, MD / Francesco Liistro, MD | |
11:30 AM - 11:35 AM | Orbital Atherectomy Vessel Preparation To Maximize DCB Efficacy In Calcified BTK Lesions: OPTIMIZE BTK RCT 2-Year Results |
Presenter(s):Thomas Zeller, MD | |
11:36 AM - 11:41 AM | The Sirolimus DCB BTK Era Begins: The Selution DCB (From MedAlliance And Cordis): Why The FDA Considered It A Breakthrough Device: Results From Singapore And Europe Are Promising And Justified The Ongoing SELUTION4BTK IDE Trial: Preliminary Results |
Presenter(s):George L. Adams, MD / Patrick J. Geraghty, MD / Michael K.W. Lichtenberg, MD | |
11:42 AM - 11:47 AM | TBD |
11:48 AM - 11:53 AM | Panel Discussion |
12:00 PM - 1:00 PM | Lunch Break – Visit Exhibits And Pavilions (2nd and 3rd Floors) |
END OF SESSION 26 | |
SESSION 27 SCHEDULE | |
Wednesday
SESSION 27:
PROGRESS IN EXOTIC AND EXTREME NEW TREATMENTS FOR VERY DISTAL LOWER EXTREMITY DISEASE CAUSING ADVANCED CLTI: OPTIONS TO SAVE THE “NO OPTION FOR TREATMENT” LIMB OR THE “DESERT FOOT”
Moderators:TBD
|
|
x | |
1:00 PM - 1:05 PM | No Option CLTI: Why Is It A Misnomer: Hybrid And Other Actual Options For Treatment And Limb Salvage |
Presenter(s):Hisham Rashid, FRCS, FRCS(Gen) | |
1:06 PM - 1:11 PM | TBD |
VALUE OF PROSTHETIC (PTFE) TIBIAL BYPASSES | |
1:12 PM - 1:17 PM | What Are The Best Options For Limb Salvage When A Single Autologous Vein Is Inadequate: Does The BEST-CLI RCT Help |
Presenter(s):Joseph L. Mills, MD | |
1:18 PM - 1:23 PM | PTFE Bypasses To Infrapopliteal Target Arteries Can Save Limbs In Patients Facing Imminent Amputation With No Other Therapeutic Option: They Can Have Worthwhile Long-Term Patency And Limb Salvage Rates: A Multicenter Experience |
Presenter(s):Hasan H. Dosluoglu, MD | |
1:24 PM - 1:29 PM | TBD |
1:30 PM - 1:35 PM | For Patients Facing Amputation With No Endo Options Or Useable Vein, PTFE Tibial Bypasses Are A Worthwhile Option That Yields Acceptable Mid-Term Patency And Long-Term Limb Salvage Rates |
Presenter(s):R. Clement Darling III, MD | |
1:36 PM - 1:41 PM | Current Outcomes With PTFE Bypasses To Infrapopliteal (Tibial) Targets: Why Is There Variability Between Surgeons And Institutions: How Does The BEST-CLI Trial Help |
Presenter(s):Matthew T. Menard, MD | |
UPDATE ON FOOT VEIN ARTERIALIZATION FOR CLTI | |
1:42 PM - 1:47 PM | Long-Term View Of The Role And Value Of Vein Arterialization: Best Way To Do It And Late Results: From The First To Make It Work |
Presenter(s):Pramook Mutirangura, FRCS (Edinburgh) | |
1:48 PM - 1:53 PM | Endovascular And Surgical Venous Arterialization For REAL No Option Patients Facing Amputation From CLTI: Does Neo-Angeogenesis Occur |
Presenter(s):Roberto Ferraresi, MD | |
1:54 PM - 1:59 PM | Pivotal US Trial (PROMISE II), US Feasibility Study (PROMISE I) And European 2-Year Registry Results With Deep Vein Arterialization With The LimFlow Device For CLTI With Gangrene Shows Reasonable Limb Salvage And Wound Healing |
Presenter(s):Daniel G. Clair, MD / Andrej Schmidt, MD / Daniela Branzan, MD | |
2:00 PM - 2:05 PM | Hybrid Superficial Venous Arterialization For REAL No Option CLTI; Step-By-Step Technical Tips And Patterns Of Failure Which Is Common |
Presenter(s):Miguel F. Montero, MD / John H. Rundback, MD, FSIR, FAHA, FSVMB | |
2:06 PM - 2:11 PM | Importance Of Open Surgical Procedures In A Limb Preservation Practice: What Are They And When Should They Be Used: It Is No longer About In Situ Vein Bypasses |
Presenter(s):Richard F. Neville, MD | |
2:12 PM - 2:18 PM | Panel Discussion |
END OF SESSION 27 | |
SESSION 28 SCHEDULE | |
Wednesday
SESSION 28:
NEW DEVELOPMENTS IN STENTS; PROSTHETIC GRAFTS; ENDOVASCULAR BYPASSES; STENT GRAFTS AND TREATMENT OF IN STENT RESTENOSIS (ISR)
Moderators:TBD
|
|
x | |
2:18 PM - 2:23 PM | The BioMimics Spiral Flow 3D Stent From Veryan Medical: 3-Year Results In CLTI Patients Show Why It Should Be The Preferred Stent For Fempop Lesions: It Is Also The Most Cost Effective |
Presenter(s):Peter Gaines, MD / Michael K.W. Lichtenberg, MD / Timothy M. Sullivan, MD | |
2:24 PM - 2:29 PM | Value Of Heparin Bonded PTFE Grafts For Femoral To Below-The-Knee Bypasses: A Systematic Review And Meta-Analysis: Are There Advantages To Propaten Grafts: Value To Crural targets |
Presenter(s):Yann Gouëffic, MD, PhD | |
2:30 PM - 2:35 PM | TBD |
PERCUTANEOUS BYPASSES | |
2:36 PM - 2:41 PM | Percutaneous (PQ) Transvenous Fempop PTFE Bypasses With The Torus 2 Device (Now From Endologix): How It Works And Updated Status Of The DETOUR And TORUS Trials In The US With 2-Year Results |
Presenter(s):Sean P. Lyden, MD / Daniel G. Clair, MD / Peter A. Schneider, MD | |
2:42 PM - 2:47 PM | Updated Late European Results Of The Detour PQ Fempop Arterial Bypass Routed Through The Femoral Vein From The DETOUR 1 Trial: Which Open Bypasses Will Be Made Obsolete |
Presenter(s):Dainis K. Krievins, MD / Peter A. Schneider, MD | |
2:48 PM - 2:53 PM | A Novel Technique For Percutaneous Extravascular Fempop Bypass - Routing A PTFE Graft Through The Soft Tissue Of The Thigh: It Is A Transcatheter Technique That Is Clampless, Sutureless, And Without External Exposure: How Is It Done; Advantages And Results |
Presenter(s):Pierre G. Sarradon, MD, MDC / Jean Pierre Becquemin, MD, FRCS | |
2:54 PM - 2:58 PM | Panel Discussion |
NEW INFORMATION ON STENT-GRAFTS | |
2:58 PM - 3:03 PM | How Can IVUS Improve Outcomes When Self-Expanding Stent-Grafts (Viabahn) Are Used To Treat SFA Occlusive Lesions: Technical Tips |
Presenter(s):Eric A. Secemsky, MD, MSc | |
3:04 PM - 3:09 PM | Can Viabahn Stent-Grafts Be Used Safely And Effectively In The SFA For CLTI: From Pooled Multicenter Data: What Are The Limitations Of These Devices |
Presenter(s):Michel M.P. Reijnen, MD, PhD | |
3:10 PM - 3:15 PM | Advantages, Limitations And Results Of Gore VBX BE Stent-Graft For Occlusive Disease In Various Vascular Beds And For F/B/EVAR Branches |
Presenter(s):Rocco Giudice, MD / Ciro Ferrer, MD, PhD | |
TREATMENT OF IN STENT RESTENOSIS (ISR) | |
3:16 PM - 3:21 PM | Update On The Excimer Laser For Treating ISR: It Has A Role In Crossing And Debulking Difficult Lesions: Technical Tips |
Presenter(s):Craig M. Walker, MD | |
3:22 PM - 3:27 PM | How Best To Treat Long Difficult Complex SFA Lesions Including Those From ISR |
Presenter(s):Sonia Ronchey, MD, PhD | |
3:28 PM - 3:34 PM | Panel Discussion And Break (Visit Exhibits And Pavilions – 2nd and 3rd Floors) |
END OF SESSION 28 | |
SESSION 29 SCHEDULE | |
Wednesday
SESSION 29:
LOWER EXTREMITY TRIALS; GUIDELINES; FOOT PERFUSION EVALUATION METHODS AND VALUE OF ANGIOSOMES
Moderators:TBD
|
|
x | |
3:40 PM - 3:45 PM | The Japanese SPINACH Registry Confirms That Open Bypasses Are Superior To Endovascular Treatments In CLTI Patients When Ischemia And Infection Are Advanced |
Presenter(s):Nobuyoshi Azuma, MD | |
3:46 PM - 3:51 PM | The Global Vascular Guidelines And WIfI Staging For CLTI Are Better Than Obsolete TASC Guidelines Because Treatment Recommendations, Revascularization Strategies And Needs For The Future Are Not Solely Based On Lesion Anatomy But Are Nuanced By Other Factors: What Are They |
Presenter(s):Michael S. Conte, MD | |
3:52 PM - 3:57 PM | Ancillary Outcomes Of The BEST-CLI RCT Comparing Endovascular And Open Treatment For CLTI When Both Treatments Are Feasible; What Are The Deficiencies IN BEST-CLI And Why Might Interventionalists Claim It Is Misleading |
Presenter(s):Alik Farber, MD, MBA / Matthew T. Menard, MD / Kenneth Rosenfield, MD | |
3:58 PM - 4:03 PM | Why Many Interventionalists Believe The Conclusions Of Best-CLI Are Misleading |
Presenter(s):Sahil A. Parikh, MD | |
4:04 PM - 4:09 PM | Key Results Findings From The Just Completed BASIL 2 RCT Comparing Open And Endovascular Treatments For Severe Leg Ischemia: How Do They Mesh With BEST CLI Results |
Presenter(s):Andrew W. Bradbury, MD, FRCSEd | |
4:10 PM - 4:18 PM | Panel Discussion |
METHODS FOR EVALUATING FOOT PERFUSION | |
4:19 PM - 4:24 PM | How And Why To Measure Foot Perfusion During And After Endo Treatments: Hyperspectral Imaging, O2 Sensors, etc: When Is The Angiosome Concept Helpful; When Not |
Presenter(s):Marianne Brodmann, MD | |
4:25 PM - 4:30 PM | New Methods For Evaluating The Significance Of Lower Extremity Arterial Lesions And Foot Perfusion Using Fractional Flow Reserve (FFR) And MRI; How They Work And Their Value In Assessing Therapeutic Success |
Presenter(s):Bijan Modarai, PhD, FRCS | |
4:31 PM - 4:36 PM | With Endovascular Treatment For CLTI With Tissue Necrosis Pedal Arch Patency Is Key To Predicting Limb Salvage: How Is It Best Evaluated |
Presenter(s):Hasan H. Dosluoglu, MD / Linda M. Harris, MD | |
4:37 PM - 4:42 PM | What Are The Best Methods For Measuring Foot Perfusion: They Are Invaluable In CLTI For Assessing Treatment Success And Predicting Healing |
Presenter(s):Werner Lang, MD | |
4:43 PM - 4:48 PM | Panel Discussion |
END OF SESSION 29 | |
SESSION 30 SCHEDULE | |
Wednesday
SESSION 30:
NEW DEVELOPMENTS IN THE TREATMENT OF INTERMITTENT CLAUDICATION (IC) AND ACUTE LIMB ISCHEMIA (ALI)
Moderators:TBD
|
|
x | |
INTERMITTENT CLAUDICATION (IC) | |
4:48 PM - 4:53 PM | A RCT After 2 Years Showed That Stent Treatment For Intermittent Claudication (IC) Improves Quality Of Life More Than Medical Treatment And Exercise: Do The Long-Term Results Refute Or Negate The 2-Year Results |
Presenter(s):Hans Lindgren, MD, PhD | |
4:54 PM - 5:00 PM | At 2 Years After Endovascular Interventions For IC, Only 32% Of Patients Were Free From Recurrent IC: From A VQI Multicenter Study: What Are The Implications |
Presenter(s):Karen Woo, MD, PhD | |
5:00 PM - 5:05 PM | When Are Invasive Vascular Treatments Justified For IC And When Are They Not: What Is The Evidence |
Presenter(s):Caitlin W. Hicks, MD, MS / James H. Black, III, MD | |
5:06 PM - 5:11 PM | TBD |
5:12 PM - 5:16 PM | Panel Discussion |
ACUTE LIMB ISCHEMIA (ALI) (See Also Session 63) | |
5:16 PM - 5:21 PM | Key Points In The Diagnosis And Treatment Of ALI In The Lower Limbs: When To Use Endovascular Treatments And When To Use Open Treatments With Thrombectomy Or A Bypass Because Such ALI Is Always Associated With Chronic Occlusive Disease |
Presenter(s):Martin Bjorck, MD, PhD | |
5:22 PM - 5:27 PM | Different Options For Thrombosuction Devices For Thrombo-Embolectomy For Treating ALI: Which Device In Which Circumstance: When Is Their Use Limited Or Ineffective |
Presenter(s):Athanasios Katsargyris, MD / Eric L.G. Verhoeven, MD, PhD | |
5:28 PM - 5:33 PM | Endovascular Mechanical Thrombectomy Is Obviating The Need For Thrombolytics In ALI: Which Device Is Best – When And Why |
Presenter(s):Patrick E. Muck, MD, FACS | |
5:34 PM - 5:39 PM | Percutaneous Vacuum Thrombectomy For ALI: Devices And Techniques: In 2023 When Is There A Role For Thrombolytics, Angioplasty, Open Balloon Catheter Thrombectomy Or A Bypass |
Presenter(s):Scott L. Stevens, MD | |
5:40 PM - 5:45 PM | What Is New With Penumbra Indigo Clot Aspiration Systems: What Makes Them Different: Indications And Contraindications |
Presenter(s):James F. Benenati, MD | |
5:46 PM - 5:51 PM | Update On How To Treat ALI Under Duplex Ultrasound Guidance: Advantages And Limitations |
Presenter(s):Natalie A. Marks, MD, RPVI, RVT, FSVM / Enrico Ascher, MD | |
5:52 PM - 5:57 PM | The STRIDE Multicenter Trial Showed That Mechanical Suction Thrombectomy With The Indigo Aspiration System (Penumbra) For Lower Limb ALI Had A Low Complication Rate And Excellent Limb Salvage: When Was Angioplasty, Stenting Or A Bypass Necessary |
Presenter(s):Thomas S. Maldonado, MD | |
5:58 PM - 6:02 PM | Panel Discussion End of Program D |
END OF SESSION 30 | |
SESSION 31 SCHEDULE | |
Wednesday
SESSION 31:
ADVANCES IN MEDICAL TREATMENTS, NEW ANTI-ATHEROGENIC DRUGS, VALUE OF RIVAROXABAN AND PREVENTING MIs IN VASCULAR SURGERY PATIENTS
Moderators:TBD
|
|
x | |
6:40 AM - 6:45 AM | When, Why And How To Lower High Triglyceride Levels: Value Of Vascepa To Decrease Cardiac Risk In Vascular Patients: Based On The REDUCE-IT RCT |
Presenter(s):Jeffrey S. Berger, MD, MS, FAHA, FACC | |
6:46 AM - 6:51 AM | New Strategies On How To Avoid And Treat Periprocedural Myocardial Infarctions (MIs) In Open Endo Vascular Surgery Patients |
Presenter(s):Peter Henke, MD | |
6:52 AM - 6:57 AM | DEBATE: LDL Cholesterol (LDL-C) Lowering And Statins For Prophylaxis Of Vascular Events Are Dangerous And Not Helpful: What Does The Latest Evidence Show |
Presenter(s):Sherif A.H. Sultan, MD, PhD, FRCS, EBQS-VASC, FACS | |
6:58 AM - 7:03 AM | DEBATE: Not So: Update On LDL-C Lowering With Statins And Other Drugs Stabilizes And Shrinks Plaques And Decreases Morbid Vascular Events: Stopping Statins Increases Patients’ Risk Of MI And Death |
Presenter(s):Ron Waksman, MD | |
7:04 AM - 7:09 AM | Update On LDL-C Lowering During A Lifetime: How Low To Strive For With Intensive Drug Therapy: How Young To Start If High; How Old To Continue Statins: Why And How Often Should LDL-C Levels Be Measured |
Presenter(s):J. David Spence, MD | |
7:10 AM - 7:15 AM | LDL-C Lowering Should Be Maximized With High Dose Statins And Ezetimibe (Zetia) To Minimize Risks From Atherosclerotic Lesions: The LDL-C Level Cannot Be Too Low And Side Effects Are Minor: LDL-C Levels Must Be Monitored And Treated To A Target Level |
Presenter(s):Anne L. Abbott, MD, PhD, FRACP | |
7:16 AM - 7:21 AM | New Findings From The VOYAGER PAD And COMPASS Trials With Low Dose Rivaroxaban (Xarelto From Janssen And J&J) And Aspirin: How Do These Drugs Lower Major Adverse Limb And Cardiac Event Rates After Lower Extremity Revascularization (Endo And Open) For PAD |
Presenter(s):Marianne Brodmann, MD / Sebastian E. Debus, MD, PhD | |
7:22 AM - 7:27 AM | How Does The Morbidity And Pathology Of Adverse Events With Arteriosclerosis Depend On Thrombosis: This Explains The Benefits Of Rivaroxaban And Aspirin Seen In The VOYAGER And COMPASS Trials |
Presenter(s):Anthony J. Comerota, MD, FACS, FACC | |
7:28 AM - 7:33 AM | New Adjunctive Drugs (Plus Statins) To Lower LDL-Cholesterol (LDL-C) In Vascular Patients: Inclisiran, Bempedoic Acid And Ezetimibe: How Do They Work And When And How To Use Them: Level Of LDL-C To Strive For: The CLEAR RCT Show That Bempedoic Acid Really Works |
Presenter(s):Richard Bulbulia, MA, MD, FRCS | |
7:34 AM - 7:42 AM | Panel Discussion |
END OF SESSION 31 | |
SESSION 32 SCHEDULE | |
Wednesday
SESSION 32:
CATHETER BASED TREATMENTS OF RESISTANT HYPERTENSION; MANAGEMENT OF CARDIAC PROBLEMS, SMOKING AND TRANSFUSION IN VASCULAR SURGERY PATIENTS; MORTALITY RISK IN STROKE PATIENTS; PREVENTING VASCULAR AND CARDIAC COMPLICATIONS
Moderators:TBD
|
|
x | |
UPDATE ON RENAL DENERVATION FOR HYPERTENSION | |
7:42 AM - 7:47 AM | Update On The Status Of Renal Denervation For Hypertension: It Is Here To Stay: Where Is It Going: Status Of The Radiofrequency Denervation SPYRAL HTN-OFF MED RCT (vs Sham) And Other Catheter Based Ablative And Ultrasound Methods (The RADIANCE II RCT Findings) |
Presenter(s):Eric A. Secemsky, MD, MSc | |
7:48 AM - 7:53 AM | Multiorgan Denervation For Treatment OF Hypertension, Diabetes And Metabolic Syndrome: How To Do It |
Presenter(s):Horst Sievert, MD | |
7:54 AM - 7:59 AM | A Precision Medicine Approach To Managing Pediatric Renovascular Hypertension: How Can Medical And Open Surgical Treatment Control It |
Presenter(s):Dawn M. Coleman, MD | |
OTHER TOPICS RELATED TO VASCULAR DISEASE AND ITS TREATMENT | |
8:00 AM - 8:05 AM | How Does The Female Sex Impact The Occurrence Of Lower Extremity Atherosclerosis, Its Treatment And Results Of Treatment |
Presenter(s):Katherine A. Gallagher, MD | |
8:06 AM - 8:11 AM | How And Why Do Thoracic Endografts For TEVAR Negatively Affect The Blood Pressure And The Heart: Can A Compliant Endograft Prevent The Problem |
Presenter(s):Juan C. Parodi, MD | |
8:12 AM - 8:17 AM | When Should Smoking Be Stopped Before AAA Repair; Before Lower Extremity Bypass: At Least 4 Weeks: Why Does The Duration Of Cessation Matters |
Presenter(s):Jeffrey J. Siracuse, MD, MBA, FACS | |
8:18 AM - 8:23 AM | Update On Limiting Transfusion And Permitting Anemia After Major Vascular Operations Increases Mortality And Serious Adverse Events Especially In Patients With Cardiac Co-Morbidities |
Presenter(s):Panos Kougias, MD, MSc | |
8:25 AM - 8:29 AM | How To Quantitate Late Mortality Risk In Asymptomatic Carotid Stenosis (ACS) Patients: Why It’s Important In Deciding To Treat ACS Patients Non-Invasively |
Presenter(s):Stavros K. Kakkos, MD, PhD / Andrew N. Nicolaides, MS, FRCS | |
8:30 AM - 8:35 AM | Secondary Prevention Of Vascular Disease And Its Complication With PCSK9 Inhibitors; When They Should Be Used And When Not: How Well Does The New Oral PCSK9 (Inhibitor MK-01616 Work) |
Presenter(s):Roxana Mehran, MD | |
8:36 AM - 8:41 AM | How Important Is Inflammation As Determined By C-Reactive Protein (CRP) Levels In Predicting Adverse Cardiac Events: What Drugs Can Lower This Risk |
Presenter(s):Ron Waksman, MD | |
8:42 AM - 8:50 AM | Panel Discussion |
8:50 AM - 9:06 AM | Break – Visit Exhibits And Pavilions (2nd and 3rd Floors) |
END OF SESSION 32 | |
SESSION 33 SCHEDULE | |
Wednesday
SESSION 33:
PROGRESS IN MANAGING ENDOLEAKS: UNDERSTANDING THEIR CONSEQUENCES AND PREDICTING, PREVENTING AND TREATING THEM
Moderators:TBD
|
|
x | |
TO TREAT OR NOT TO TREAT TYPE 2 ENDOLEAKS | |
9:06 AM - 9:11 AM | Active AAA Sac Management With Polymers: This Is The Missing Link To Improve Outcomes After EVAR: Technique And Results From The SHAPE AAA Trial (From Shape Memory) |
Presenter(s):Michel M.P. Reijnen, MD, PhD / Andrew Holden, MBChB | |
9:12 AM - 9:17 AM | Fibrin Glue Sac Filling Technique During EVAR To Prevent All Endoleaks: It Should Be Routine And Is A Game Changer Based On A Multicenter Trial: How To Do It |
Presenter(s):Qingsheng Lu, MD | |
TREATING TYPE 1 ENDOLEAKS | |
9:18 AM - 9:23 AM | Post EVAR Type 1A Endoleaks Are Predictable And Preventable: Strategies To Prevent Them Or Treat Them |
Presenter(s):Michael J. Singh, MD | |
9:24 AM - 9:29 AM | Can Gluing Be Effective Treatment For Small Type 1A Endoleaks: Under What Circumstances And Technique |
Presenter(s):Thomas S. Maldonado, MD / Neal S. Cayne, MD | |
9:30 AM - 9:35 AM | When And How To Use Embolization Coils To Treat Type 1A Endoleaks Successfully: When Won’t Coils Work: How To Diagnose Type 1A Endoleaks Accurately |
Presenter(s):Sigrid Nikol, MD | |
9:36 AM - 9:41 AM | How To Minimize Gutter Type 1A Endoleaks With Chimney EVAR (Ch/EVAR): How Does A Standard Protocol Help; How To Treat Them When They Occur |
Presenter(s):David J. Minion, MD | |
9:42 AM - 9:48 AM | Panel Discussion |
9:49 AM - 9:54 AM | A RCT Shows The Advantages Of Inferior Mesenteric Artery (IMA) And Lumbar Embolization: The Next Generation Of EVAR Endografts Must Prevent Endoleaks: How Can It Be Done |
Presenter(s):Dominique Fabre, MD, PhD / Stephan Haulon, MD | |
9:55 AM - 10:00 AM | Preventing Threatening Type 2 Endoleaks By IMA Embolization When AAA Sac And IMA Are Large: Indications And Technical Tips And Evidence |
Presenter(s):Toru Kuratani, MD, PhD | |
10:01 AM - 10:06 AM | With A Large IMA (> 3mm), When Should It Be Embolized; Or When Should It Be Revascularized: How And Why |
Presenter(s):Piotr M. Kasprzak, MD | |
10:07 AM - 10:12 AM | Reduction Of Type 2 Endoleaks By Pre-Emptive Coiling Of Aortic Side Branches >3 mm: How Do We Know Based On A Mid-Term Analysis |
Presenter(s):Götz M. Richter, MD, PhD | |
10:13 AM - 10:19 AM | Panel Discussion |
TREATMENT OF TYPE 2 ENDOLEAKS AND ENDOTENSION AFTER EVAR | |
10:20 AM - 10:25 AM | Transcaval Approach To Treat Type 2 Endoleaks After EVAR: Indications: Technique; Precautions And Results |
Presenter(s):Ross Milner, MD | |
10:26 AM - 10:31 AM | Glue Embolization Is Effective Treatment For Most Threatening Type 2 Endoleaks: When And How Best To Do It: Limitations |
Presenter(s):Neal S. Cayne, MD | |
10:32 AM - 10:37 AM | TBD |
10:38 AM - 10:43 AM | How To Use 3D Fusion Software (GE) To Get Into The Nidus And Treat Type 2 Endoleaks: Best Embolic Agent And Alternate Approaches (Transgraft Or Transcaval) For Access: How To Seal The Graft Puncture Site |
Presenter(s):Mark W. Mewissen, MD, RVT | |
10:44 AM - 10:49 AM | Laser Assisted Transgraft Onyx Embolization Of Type 2 Endoleaks: Indications, Equipment And Technique |
Presenter(s):Zvonimir Krajcer, MD, FACC | |
10:50 AM - 10:55 AM | Most Type 2 Endoleaks After EVAR Should Be Left Alone Because Treatments Have Poor Results, Have Complications And Do Not Improve Outcomes: Are There Exceptions |
Presenter(s):Hence J.M. Verhagen, MD, PhD | |
10:56 AM - 11:01 AM | With Type 2 Endoleaks And Sac Expansion, Open Sacotomy And Branch Ligation Is Often The Best Treatment: What Precautions Are Needed In Case There Is An Occult Type 1 Leak |
Presenter(s):Zachary M. Arthurs, MD | |
11:02 AM - 11:11 AM | Panel Discussion |
END OF SESSION 33 | |
SESSION 34 SCHEDULE | |
Wednesday
SESSION 34:
TCT AND PLINIO ROSSI RECORDED LIVE COMPLEX AND CHALLENGING ENDOVASCULAR CASES
Moderators:TBD
|
|
x | |
TCT RECORDED LIVE CHALLENGING ENDOVASCULAR CASES | |
Moderator(s): Juan F. Granada, MD / Sahil A. Parikh, MD | |
11:12 AM - 11:36 AM | PROGRAM TO BE DETERMINED |
PLINIO ROSSI’S RECORDED LIVE COMPLEX AND CHALLENGING ENDO CASES | |
Moderator(s): Fabrizio Fanelli, MD, EBIR / Andrew Holden, MBChB / Carlo Setacci, MD | |
11:36 AM - 12:00 PM | PROGRAM TO BE DETERMINED |
12:00 PM - 1:00 PM | Lunch Break – Visit Exhibits And Pavilions (2nd and 3rd Floors) |
END OF SESSION 34 | |
SESSION 35 SCHEDULE | |
Wednesday
SESSION 35:
RECORDED LIVE CHALLENGING CASES AND INNOVATIVE TECHNIQUES FROM THE LINC GROUP
Moderators:TBD
|
|
x | |
1:00 PM - 1:32 PM | PROGRAM TO BE DETERMINED |
END OF SESSION 35 | |
SESSION 36 SCHEDULE | |
Wednesday
SESSION 36:
ISSUES IMPORTANT IN VASCULAR SURGERY: PRACTICE PATTERNS, HISTORY, EFFICIENCY, MALPRACTICE, SCIENCE, TRAINING AND HUMAN BEHAVIOR
Moderators:TBD
|
|
x | |
1:33 PM - 1:38 PM | Care Fragmentation In Vascular Treatment: What Is It; What Are Its Causes And What Is Its Impact On Outcomes After Vascular Procedures |
Presenter(s):Olamide Alabi, MD / William D. Jordan Jr., MD | |
1:39 PM - 1:44 PM | History Of Women In Surgery And Vascular Surgery: What Does The Future Hold Within The Next 10 Years |
Presenter(s):Cynthia K. Shortell, MD | |
1:45 PM - 1:50 PM | How To Improve Operating Room Efficiency For Vascular Surgical Operations: Why Is Inefficiency In This Setting So Widespread And Hard To Fix |
Presenter(s):Panos Kougias, MD, MSc | |
1:51 PM - 1:56 PM | Patient Reported Outcomes (PROs): What Are They: Importance And Pitfalls: How Do They Differ From Patient Satisfaction |
Presenter(s):Christopher J. Smolock, MD | |
1:57 PM - 2:02 PM | Why Non-Compete Clauses In Contracts Should be Eliminated By Law: The SVS Position In Favor Of Such Law Contrasts With The AHA Position Against |
Presenter(s):Margaret C. Tracci, MD, JD | |
2:03 PM - 2:08 PM | Why Systematic Reviews, Meta-Analyses And RCTs Can Be Misleading: What To Do About It: Does Current Wisdom Help |
Presenter(s):Janet T. Powell, MD, PhD | |
ISSUES IN VASCULAR TRAINING | |
2:09 PM - 2:14 PM | Optimal New Training Paradigm For Vascular Surgeons: 0+5 Vascular Surgery Residency Followed By 2 Years Of Cardiac Surgery Residency Training: Why Is It Better Than 2 Extra Years Of Laboratory Research |
Presenter(s):Alan B. Lumsden, MD, FACS | |
2:15 PM - 2:20 PM | Integrated (0+5) Vascular Residency Plus CT Surgery Fellowship – How Many Are There; Are They Over Trained And Underutilized: How Has It Helped Me |
Presenter(s):Jennifer L. Perri, MD, MBA | |
2:21 PM - 2:26 PM | Is Vascular Surgery Facing A Looming Decline Because Of Inadequate Numbers Of Both 5+2 And 0+5 Training Programs: What Should And Can Be Done About It: What Are The Impediments |
Presenter(s):Michael B. Silva, Jr., MD | |
2:27 PM - 2:32 PM | How To Remedy The Deficiency Vascular Fellows And Residents Have In Their Numbers Of Open Vascular Surgical Operations: When Should They Get Additional Subspecialty Training In Another Institution |
Presenter(s):Malachi Sheahan, MD | |
2:33 PM - 2:38 PM | TBD |
2:39 PM - 2:44 PM | How Human Behavior – Even With Vascular Specialists – Is Controlled By Biases And Rationalizations: How To Overcome These And Perform Better |
Presenter(s):Scott L. Stevens, MD | |
2:45 PM - 2:58 PM | Panel Discussion And Break (Visit Exhibits And Pavilions – 2nd and 3rd Floors) |
END OF SESSION 36 | |
SESSION 37 SCHEDULE | |
Wednesday
SESSION 37:
MORE ISSUE-RELATED TOPICS IMPORTANT TO VASCULAR SURGEONS AND VASCULAR SPECIALISTS; ISSUES RELATED TO OUTPATIENT CENTERS OR OFFICE BASED LABS (OBLs)
Moderators:TBD
|
|
x | |
2:58 PM - 3:03 PM | How COVID And Changes In The Economy Have Caused Hospitals To Run Out Of Money; What Is The Resulting Impact On Vascular Care And Vascular Doctors; What Can Be Done About It |
Presenter(s):Samuel R. Money, MD, MBA | |
3:04 PM - 3:09 PM | DEBATE: How Heart And Vascular Centers Are Attracting Private Equity Investment Leading To Benefits For All Concerned Including Vascular Surgeons And Their Patients |
Presenter(s):Jean Bismuth, MD | |
3:10 PM - 3:15 PM | DEBATE: Heart And Vascular Centers Are Artificial Entities That Disadvantage Vascular Surgeons And Don’t Improve Patient Care |
Presenter(s):Malachi Sheahan, MD | |
3:16 PM - 3:21 PM | Vascular Spinoff Revenue In Tertiary Healthcare Systems: Substantially More Downstream Benefits FROM Vascular Surgeons: How To Make Hospital Administrators Appreciate The Value Of Vascular Surgeons And Reward Them Appropriately |
Presenter(s):Joseph V. Lombardi, MD, MBA | |
ISSUES RELATED TO OUTPATIENT CENTERS AND OBLs | |
3:22 PM - 3:27 PM | The Ever Changing Reimbursement For Lower Extremity Endovascular Therapies In Hospitals And OBLs: Why It’s Happening And Where Is It Going |
Presenter(s):Sean P. Roddy, MD / Robert M. Zwolak, MD, PhD | |
3:28 PM - 3:33 PM | Strategies To Succeed In An OBL Despite Continuing Cuts In CMS Reimbursement |
Presenter(s):Clifford M. Sales, MD, MBA, FACS | |
3:33 PM - 3:39 PM | Panel Discussion |
MORE ISSUES RELATED TO OUTPATIENT CENTERS AND OBLs | |
3:40 PM - 3:45 PM | DEBATE: OBLs Are Bad: Why I Choose Not To Work In An OBL |
Presenter(s):Dipankar Mukherjee, MD | |
3:46 PM - 3:51 PM | DEBATE: Not True! How Can OBLs Provide Good Vascular Care With Excellent Results, Be Profitable And Still Allow Vascular Surgeons To Only Work From 8 AM To 5 PM |
Presenter(s):Mark A. Mattos, MD | |
3:52 PM - 3:57 PM | How To Make Out-Patient Vascular Treatment Facilities (OBLs, ASCs) Safe, Effective And Profitable Without Doing Unjustified Procedures |
Presenter(s):Christopher J. Kwolek, MD, MBA | |
3:58 PM - 4:03 PM | Comparison of Arterial Closure Devices In An OBL Setting: Which Is Best Based On An Experience With 19000 Cases |
Presenter(s):Sam S. Ahn, MD, FACS, MBA | |
4:04 PM - 4:09 PM | Tips For Performing High-Risk Lower Extremity Endovascular Procedures Including Redos Safely And Effectively In An OBL |
Presenter(s):Anil P. Hingorani, MD / Enrico Ascher, MD | |
4:10 PM - 4:15 PM | OBL Audits: What Are They Looking For And How To Avoid Civil And Criminal Penalties: Do Practice Guidelines Help Or Harm |
Presenter(s):O. William Brown, MD, JD | |
4:16 PM - 4:21 PM | Panel Discussion |
END OF SESSION 37 | |
SESSION 38 SCHEDULE | |
Wednesday
SESSION 38:
UPDATES AND ISSUES IMPORTANT TO ALL VASCULAR SURGEONS AND SPECIALISTS: FUTURE REIMBURSEMENT; VASCULAR REGISTRIES AND THE VQI, VALUE OF GUIDELINES AND RCTs: THE FDA: STAISTICS; EVIDENCE BASED MEDICINE; MISCELLANEOUS
Moderators:TBD
|
|
x | |
4:22 PM - 4:27 PM | What Obstacles And Blows Are Vascular Surgeons And Other Vascular Specialists Facing In 2023: Will Planned Increased Reimbursement For Office And Hospital Visits Cause More Decreases In Procedural Reimbursements |
Presenter(s):Sean P. Roddy, MD | |
4:28 PM - 4:33 PM | VQI Collaboration With The International Consortium of Vascular Registries (ICVR): How Can It Better Evaluate Aortic Endograft Performance In Ruptured Aneurysms |
Presenter(s):Adam Beck, MD | |
4:34 PM - 4:39 PM | The Role And Value Of Guidelines And RCTs In Vascular Practice; Why Guidelines And RCTs Can Be Misleading: What To Do About The Problem |
Presenter(s):Anders Wanhainen, MD, PhD | |
REGULATORY AND FDA ISSUES | |
4:40 PM - 4:45 PM | How Can A Device Qualify With The FDA For BREAKTHROUGH Status And How Does It Differ From SAFER Status |
Presenter(s):Valerie M. Merkle, PhD | |
4:46 PM - 4:51 PM | Past, Present And Future Collaboration Between Industry, Clinicians And The FDA To Address Unmet Clinical Needs: We Should Not Be Adversaries |
Presenter(s):Dorothy B. Abel, BSBME | |
EVIDENCE BASED MEDICINE ISSUES | |
4:52 PM - 4:57 PM | Improved And Simplified Clinical Trial Statistics For Dummies: Why p Values Are Decreasing In Importance And Bayesian Statistics Are Increasing In Importance: What Is The Latter |
Presenter(s):Charles C. Miller, PhD | |
4:58 PM - 5:03 PM | Registry Based RCTs: What Are They And Why Are They Better Than Other Evidence Based Techniques |
Presenter(s):Jens Eldrup-Jorgensen, MD / Jack L. Cronenwett, MD | |
5:04 PM - 5:09 PM | Panel Discussion |
MISCELLANEOUS | |
5:10 PM - 5:15 PM | Managing Various Specialties And Generations Of Specialists In A Multi-Specialty Vascular Institute Or Center: How To Satisfy Everyone And Optimize Patient Outcomes |
Presenter(s):Gary M. Ansel, MD | |
5:16 PM - 5:21 PM | Despite What The New York Times And Others Say, Close Relationships Of Vascular Surgeons With Industry Are Mostly Ethical And Beneficial To Patients And Society: Pitfalls To Avoid |
Presenter(s):Bruce A. Perler, MD, MBA | |
5:22 PM - 5:27 PM | Innovation In Vascular Surgery: Ideas, Funding, Partners And Intellectual Property: How To Turn Fantasy Into Reality |
Presenter(s):Jeffrey H. Lawson, MD, PhD | |
5:28 PM - 5:33 PM | Current Quality Analysis For Vascular Surgeons And Vascular Specialists Does Not Reflect Quality Of Care: Why And What Can Be Done About It |
Presenter(s):Richard F. Neville, MD | |
5:34 PM - 5:39 PM | Editorial Update On The JVS And All Its Progeny: Its Status And How It Will Be Improved |
Presenter(s):Ronald L. Dalman, MD / Thomas L. Forbes, MD | |
5:40 PM - 5:45 PM | Effects Of The Affordable Care Act (ACA) On Vascular Surgical Outcomes: Does The Medicaid Expansion Of The ACA Improve Outcomes Or Not |
Presenter(s):Mohammad H. Eslami, MD, MPH | |
5:46 PM - 5:52 PM | Panel Discussion End of Program E |
END OF SESSION 38 | |
SESSION 39 SCHEDULE | |
Wednesday
SESSION 39:
MORE TOPICS RELATED TO THE THORACIC AORTA, AORTIC DISSECTIONS, INTRAMURAL HEMATOMAS (IMHs), INFLAMMATORY ANEURYSMS AND THEIR TREATMENT
Moderators:TBD
|
|
x | |
6:50 AM - 6:55 AM | What Is Best Medical Treatment For TBAD Patients: How Best To Control Blood Pressure And To Get Patients To Comply: They Don’t |
Presenter(s):Colin D. Bicknell, MD, FRCS | |
6:56 AM - 7:01 AM | Requirement For Adjunctive Branch Stents After TEVAR For Complicated TBADs Is An Indicator Of Poor Prognosis: What Can Be Done To Offset It |
Presenter(s):Mark K. Eskandari, MD | |
7:02 AM - 7:07 AM | Current Optimal Management Of Intramural Hematomas (IMH): Which Ones Should Be Treated With TEVAR And What Is The Best Extent Of Aortic Coverage |
Presenter(s):Frank J. Criado, MD | |
7:08 AM - 7:13 AM | Outer/ Inner/Upward Branches Or Fenestrations: Strategies For Complex Aortic Repair For Patients With Chronic TBADs: What Are The Unmet Needs |
Presenter(s):Bijan Modarai, PhD, FRCS | |
7:14 AM - 7:19 AM | Current Advances In The Treatment For Inflammatory Aneurysms: How Effective Are EVAR And TEVAR |
Presenter(s):Furuzan Numan, MD | |
7:20 AM - 7:25 AM | Panel Discussion |
7:25 AM - 7:30 AM | DEBATE: The Stabilize Technique Will Lead To Paradigm Shift In The Treatment Of TBADs And Will Replace Most False Lumen Occlusion Devices And F/B/EVAR Treatments: It Relaminates The Aorta And Eliminates The False Lumen: How To Do It And Precautions |
Presenter(s):Igor A. Laskowski, MD, PhD / Josh B. Goldberg, MD / Heepeel Chang, MD | |
7:31 AM - 7:36 AM | DEBATE: Not So Fast! A Multimodular Approach To Treating Chronic TBADs With TAAAs: Who Needs A F/B/EVAR; Who Needs A Candy-Plug Or Other Occlusion Technique |
Presenter(s):Tilo Koelbel, MD, PhD / Fiona Rohlffs, MD | |
7:37 AM - 7:42 AM | When Are Thoracic Endografts Valuable Treatments For Genetic Aortopathies |
Presenter(s):Cherrie Z. Abraham, MD | |
7:43 AM - 7:48 AM | What Are The Knowledge Gaps In The Treatment Of TBADs: How Can And Will They Be Resolved |
Presenter(s):Colin D. Bicknell, MD, FRCS | |
7:49 AM - 7:54 AM | A Recently Funded Multicenter NIH Grant (IMPROVE-AD) To Evaluate Unknowns In The Treatment Of Acute And Subacute TBADs: What Will It Tell Us And When And Why Was It So Hard To Get It Approved: Are There Other Similar RCTs OUS |
Presenter(s):Firas F. Mussa, MD / Gustavo S. Oderich, MD FACS | |
7:55 AM - 8:00 AM | Panel Discussion |
END OF SESSION 39 | |
SESSION 41 SCHEDULE | |
Wednesday
SESSION 41:
OPEN AND ENDO TREATMENT OF COMPLEX AAAs (JUXTA, PARA- AND SUPRA-RENAL) AND TAAAs; NEW DEVICES FOR THEIR TREATMENT
Moderators:TBD
|
|
x | |
COMPLEX AAAs AND TAAAs | |
9:24 AM - 9:29 AM | Aortic Neck Dilatation And AAA Sac Shrinkage After F/EVAR Is Better Than After Standard EVAR |
Presenter(s):Thomas S. Maldonado, MD | |
9:30 AM - 9:35 AM | Recent Progress In Prevention Of Spinal Cord Ischemia (SCI) Especially Paraplegia After Complex AAA And TAAA Endovascular Repairs |
Presenter(s):Matthew J. Eagleton, MD | |
9:36 AM - 9:41 AM | Complete Aortic Endovascular Repairs (Zones 0-10) Using Parallel Endografts With A Docking Station: How And Why To Make Them Work Effectively Despite Doubts About Parallel Grafts |
Presenter(s):Manish Mehta, MD, MPH | |
9:42 AM - 9:47 AM | Value Of Ch/EVAR For Juxtarenal AAAs: They Are As Safe And Effective As Any Other Procedure And Simpler: Based On A Meta-Analysis Of Mid-Term Outcomes |
Presenter(s):Joost van Herwaarden, MD, PhD | |
9:48 AM - 9:53 AM | Key Findings From The UK-Complex Aneurysm Study (UK-COMPASS) Comparing Outcomes Of Off-Label EVAR, Open Repair And F/EVAR For Short Necked AAAs |
Presenter(s):S. Rao Vallabhaneni, MD, FRCS | |
9:54 AM - 9:59 AM | Comparison Of Endo And Open Repair Of Post Dissection TAAAs: Which Procedure Is Best And When |
Presenter(s):Fabio Verzini, MD, PhD, FEBVS | |
10:00 AM - 10:05 AM | What Is A Hybrid Repair Of A TAAA (Proximal Endograft + Distal Open Repair - The Upchurch Procedure): When Is It Indicated; What Are the Advantages And Results |
Presenter(s):Gilbert R. Upchurch, MD / Sal Scali, MD / Dean Arnaoutakis, MD | |
10:06 AM - 10:12 AM | Panel Discussion |
TOPICS RELATED TO INTERESTING NEW DEVICES | |
10:12 AM - 10:17 AM | Update Of A New Hybrid Device (Thoracoflo From Terumo Aortic) For TAAA Repair: How It Works, Clinical Experience And Advantages |
Presenter(s):Sebastian E. Debus, MD, PhD | |
10:18 AM - 10:23 AM | How To Prevent Patch Aneurysms After Open TAAA Repair With Long Antegrade Grafts: How To Treat Them When They Occur |
Presenter(s):Manju Kalra, MBBS | |
10:24 AM - 10:29 AM | Can EVAR And F/EVAR Be Done Under Local Anesthesia: Can They Become Outpatient Procedures Or Office Based Lab Procedures: What Are The Contraindications |
Presenter(s):Michael C. Stoner, MD | |
10:30 AM - 10:35 AM | WeFlow Device For Juxtarenal AAA, TAAA And Arch Repairs: A New Inner Branch And Outer Branch Approach: How Does It Work And Promising Results |
Presenter(s):Wei Guo, MD | |
10:36 AM - 10:40 AM | Panel Discussion |
END OF SESSION 41 | |
SESSION 42 SCHEDULE | |
Wednesday
SESSION 42:
PROGRESS IN TREATING ILIAC ANEURYSMS; ILIAC BRANCHED DEVICES (IBDs); UPDATE ON MULTILAYER FLOW MODULATING (MLFM) AND OTHER BARE STENTS FOR TREATING ANEURYSMS AND DISSECTIONS
Moderators:TBD
|
|
x | |
TREATMENT OF ILIAC ANEURYSMS AND IBDs | |
10:40 AM - 10:45 AM | Surprisingly Occlusion Of 1 Or Both Hypogastric Arteries During EVAR Does NOT Result In Serious Adverse Events: From A Large VQI Study |
Presenter(s):Heepeel Chang, MD | |
10:46 AM - 10:51 AM | Update On The Gore IBE Excluder For Treating Iliac Aneurysms And Preserving Hypogastric Artery Flow: Why It Should Be Preserved Whenever Possible: When Can It Not Be |
Presenter(s):Michel M.P. Reijnen, MD, PhD | |
10:52 AM - 10:57 AM | Updated Experience Including The US-ARC Data With Cook IBD For The Treatment Of Common Iliac Aneurysms: Including After Previous EVAR |
Presenter(s):Giovanni B. Torsello, MD / Carlos H. Timaran, MD / Andres Schanzer, MD | |
10:58 AM - 11:03 AM | Long-Term Comparison Of The Cook Zenith And Gore Excluder IBDs: Advantages And Limitations Of Both: What Is Currently The Best Bridging Stent |
Presenter(s):Giovanni Pratesi, MD | |
11:04 AM - 11:09 AM | An Iliac Customized Fenestrated Device (From Terumo Aortic): When And How Can It Work In Anatomies Unsuitable For Branched Endografts: Advantages And Limitations |
Presenter(s):Afshin Assadian, MD / Fadi Taher, MD | |
11:10 AM - 11:15 AM | Update On The Advantages Of The Artivion (Formerly CryoLife/Jotec) IBD Device Now From Artivion For Treating Common And Internal Iliac Artery Aneurysms: When Bell Bottom Technique; When IBD: From The PLIANT II Study |
Presenter(s):Lee Bouwman, MD, PhD, MSc | |
11:16 AM - 11:22 AM | Panel Discussion |
UPDATE ON MULTILAYER FLOW MODULATING (MLFM) AND OTHER BARE STENTS | |
11:22 AM - 11:27 AM | Why MLFM Bare Stents Should Be The Treatment Of Choice For Visceral, Peripheral And Iliac Aneurysms: Advantages And Has Rupture Been Universally Prevented: What About For TAAAs |
Presenter(s):Michel C. Henry, MD | |
11:28 AM - 11:33 AM | Is There A Role For Bare Stents (Allay From Intressa, Formerly Cardiatis) In The Treatment Of Type A Aortic Dissections (TAADs) |
Presenter(s):Rodney A. White, MD | |
11:34 AM - 11:39 AM | 8-Year Clinical Experience With Bare Stent Treatment Of TAADs |
Presenter(s):Ivo Petrov, MD, PhD / Victor S. Costache, MD, PhD | |
11:40 AM - 11:45 AM | 3-Year Experience With Bare Stents (Allay From Intressa, Formerly Cardiatis) For The Treatment Of TAADs |
Presenter(s):Claude D. Vaislic, MD | |
11:46 AM - 11:51 AM | Role Of Bare Metal AMDS Stents From Artivion (Formerly CryoLife/Jotec) For Repair Of Acute Type A Dissections: Indications And Results |
Presenter(s):Wilson Y. Szeto, MD / Grayson H. Wheatley, MD | |
11:52 AM - 12:00 PM | Panel Discussion |
12:00 PM - 1:00 PM | Lunch Break – Visit Exhibits And Pavilions (2nd and 3rd Floors) |
END OF SESSION 42 | |
SESSION 43 SCHEDULE | |
Wednesday
SESSION 43:
MORE NEW DEVELOPMENTS IN AAA TREATMENT AND STANDARD EVAR: A NEW DEVICE TO SLOW AAA GROWTH; AAA NECK DILATATION AFTER EVAR; VALUE OF LOW PROFILE AAA ENDOGRAFTS; LINK TO CANCER; IMPROVED ULTRASOUND SURVEILLANCE AND ALL AAAs ARE NOT TIME BOMBS WAITING TO EXPLODE
Moderators:TBD
|
|
x | |
1:00 PM - 1:05 PM | Update On A Novel New Technology (Nectero) To Slow AAA Growth; How Does It Work And 3-Year Clinical Results |
Presenter(s):Venkatesh G. Ramaiah, MD | |
1:06 PM - 1:11 PM | Decreasing Frequency Of Elective And Ruptured AAA Repairs Is Due To Epidemiology Rather Than Other Factors Like Screening |
Presenter(s):Ian Loftus, MD / Pete Holt, MD, PhD | |
AAA NECK BEHAVIOR AFTER EVAR | |
1:12 PM - 1:17 PM | Optimal Stent Design And Optimal Degree Of Oversizing To Avoid Neck Dilatation And Why It Matters |
Presenter(s):Carlos F. Bechara, MD | |
1:18 PM - 1:23 PM | Major Aortic Neck Dilatation Occurs Equally After EVAR And Open Repair: From The DREAM RCT: This ONLY Occurs After EVAR With Self-Expanding Endografts |
Presenter(s):Jan D. Blankensteijn, MD | |
1:24 PM - 1:29 PM | What Should Be The Role OF Physician Modified Endografts (PMEGs) For the Treatment Of Short Or No Neck AAAs When Industry Made F/EVAR Devices Are Available: PMEG Are Only Good In Some Centers |
Presenter(s):Benjamin W. Starnes, MD | |
1:30 PM - 1:35 PM | DEBATE: Low Profile Devices For EVAR Are Failing: Their Future Is Questionable Based On Results Of Other Devices Like The Endurant Endograft At 10 Years (From The ENGAGE OUS Registry) |
Presenter(s):Hence J.M. Verhagen, MD, PhD | |
1:36 PM - 1:41 PM | DEBATE: Not So: Ovation Stent-Grafts (From Endologix) Have Good 5-Year Results With No Neck Dilatation Or Migration Even With Challenging Neck Anatomy: Based On A Multicenter International Study Of A Low Profile Endograft |
Presenter(s):Mahmoud B. Malas, MD, MHS | |
1:42 PM - 1:47 PM | Is AAA Thrombus More Dangerous In Women Than In Men: What Are The Dangers Of Such Thrombus |
Presenter(s):Janet T. Powell, MD, PhD | |
1:48 PM - 1:53 PM | How Well Does Non-Fluoroscopic Guidance Using The IOPS System From Centerline Work For Performance Of Standard EVAR: Findings From The MOTION Trial |
Presenter(s):Francis J. Caputo, MD | |
1:54 PM - 1:59 PM | Despite Great Advances With AAA Management, Little Progress Has Been Made In 2 Important Areas: Improving Indications For Treatment And Precision Of Measurement: AAAs ≤6.0 cm Rarely Rupture |
Presenter(s):Frank J. Criado, MD | |
2:00 PM - 2:06 PM | Panel Discussion |
END OF SESSION 43 | |
SESSION 44 SCHEDULE | |
Wednesday
SESSION 44:
MORE NEW DEVELOPMENTS IN AAAs: HOW DOES THROMBUS LOAD EFFECT PROGNOSIS AFTER EVAR AND EVAS; OTHER RELATED AAA TOPICS
Moderators:TBD
|
|
x | |
AAA SAC THROMBUS LOAD | |
2:06 PM - 2:11 PM | Impact Of Thrombus In AAA Sac And Neck On AAA Behavior And EVAR Outcomes: How To Quantitate Thrombus Load And Distribution |
Presenter(s):Nicos Labropoulos, BSc (Med), PhD, DIC, RVT | |
2:12 PM - 2:17 PM | DEBATE: Large Amount Of AAA Sac Thrombus Promotes Morbidity Without Rupture And With Rupture: By What Mechanisms Is Thrombus Harmful And How Can Thrombus Load Be Quantitated |
Presenter(s):David H. Deaton, MD, FACS | |
2:18 PM - 2:23 PM | DEBATE: Large Flow Luminal Space In An AAA Sac With Minimal Mural Thrombus Is Associated With Adverse Events After EVAR: It Is More Important Than AAA Sac Size: Thrombus May Be Protective |
Presenter(s):Hence J.M. Verhagen, MD, PhD | |
OTHER AAA RELATED TOPICS | |
2:24 PM - 2:29 PM | Graft Infolding: A Unique EVAR Complication: How To Prevent It And How To Treat It |
Presenter(s):Ashraf Mansour, MD | |
2:30 PM - 2:35 PM | With Aneurysmal Disease What Causes The Aorta To Rotate: What Is The Impact Of Counterclockwise Rotation Of The Aneurysmal Aorta |
Presenter(s):Nicos Labropoulos, BSc (Med), PhD, DIC, RVT | |
2:36 PM - 2:41 PM | Observation For Small AAAs (< 5. 0 cm) Is Safe And Does Not Impair Future EVAR Options |
Presenter(s):Jon S. Matsumura, MD | |
2:42 PM - 2:47 PM | Life Altering Events After Endovascular Aortic Repairs Include Death, Dialysis, Paralysis Or Stroke: The Incidence Of These Events Varies Markedly Depending On The Level Of Repair |
Presenter(s):Marc L. Schermerhorn, MD | |
2:48 PM - 2:53 PM | Update On Technical Tips To Perform SAFE Large Sheath Percutaneous Femoral Access And Closure For Complex AAA EVAR In Obese Or Scarred Groins – Even With Calcified Arteries: It Is Almost Always Possible |
Presenter(s):Barend M.E. Mees, MD, PhD, FEBVS | |
2:54 PM - 2:59 PM | Increased Inflammatory Biomarkers And Increased 18F FDG Uptake On PET CT In AAA Patients Are Associated With Rapid Growth And Worse Long-Term Survival: Should These Markers Be Tested Routinely And How Should AAA Treatment Be Modified If They Are Elevated |
Presenter(s):Natzi Sakalihasan, MD, PhD | |
3:00 PM - 3:06 PM | Panel Discussion |
3:06 PM - 3:15 PM | Break – Visit Exhibits And Pavilions (2nd and 3rd Floors) |
END OF SESSION 44 | |
SESSION 45 SCHEDULE | |
Wednesday
SESSION 45:
HOT AORTIC TOPICS
Moderators:TBD
|
|
x | |
3:15 PM - 3:20 PM | Aorto-Enteric Fistulas Associated With Infected EVARS Or Open Prosthetic Grafts; What Are The Differences Between Them And What Are the Implications For Treatment |
Presenter(s):Sal Scali, MD | |
3:21 PM - 3:26 PM | Late Delayed Renal Artery Revascularization After Inadvertent Occlusion For Many Days Is Worthwhile: Collaterals Keep The Kidney Viable Although No Urine Is Produced |
Presenter(s):Nikolaos Tsilimparis, MD, PhD | |
3:27 PM - 3:32 PM | Impact Of COVID, The NICE Guidelines And Changing Disease Patterns On AAA Practice In The UK: Which Is Most Important |
Presenter(s):Ian Loftus, MD / Pete Holt, MD, PhD | |
3:33 PM - 3:38 PM | TEVAR For Acute Complicated TBAD: Improved Outcomes When The Endograft Is Extended To Zone 2 Versus Zone 3: Why Is This So And What To Do About The Subclavian Artery |
Presenter(s):Jean M. Panneton, MD | |
3:39 PM - 3:44 PM | Safe Anticoagulation In F/B/EVAR Patients Requiring Spinal Fluid Drainage |
Presenter(s):Afshin Assadian, MD | |
3:45 PM - 3:50 PM | Panel Discussion |
3:50 PM - 3:55 PM | Are We Overtreating AAAs: The Current Diameter Threshold For AAA Repair Is No Longer Relevant: Based On New Scrutiny Of Old Trials And A Meta-Analysis Of AAA Rupture Risk |
Presenter(s):Timothy A. Resch, MD, PhD | |
3:56 PM - 4:01 PM | What Is “Failure To Rescue” After Endovascular TAAA Repairs: What Factors Are Responsible And Why Is It Important |
Presenter(s):Jade S. Hiramoto, MD | |
4:02 PM - 4:07 PM | Laser In Situ F/EVAR As An Off-The-Shelf Option For Ruptured Complex Or Short Necked AAAs And Failed EVAR: Experience And Technical Tips |
Presenter(s):Timothy A. Resch, MD, PhD | |
4:08 PM - 4:13 PM | 9-Year Experience Shows The Safety And Effectiveness Of Endoanchors For F/EVAR: They Support Shortening Main Endograft Length And Reducing Procedural Complexity |
Presenter(s):Jörg Tessarek, MD | |
4:14 PM - 4:19 PM | Risk Factors And Late Clinical Consequences Of AAA Neck Dilatation After EVAR With Self-Expanding Endografts: What Are The Differences In Neck Behavior After Excluder And Endurant Endografts: Based On 10-Year Results From The ENGAGE Registry |
Presenter(s):Hence J.M. Verhagen, MD, PhD | |
4:20 PM - 4:25 PM | Panel Discussion |
END OF SESSION 45 | |
SESSION 46 SCHEDULE | |
Wednesday
SESSION 46:
MORE SHORT HOT NEW TOPICS RELATED TO AORTO-ILIAC AND CAROTID DISEASE AND THEIR TREATMENTS
Moderators:TBD
|
|
x | |
4:26 PM - 4:31 PM | Are Low Profile Devices For EVAR And TEVAR Improving Or Worsening Outcomes |
Presenter(s):Naoki Fujimura, MD, PhD | |
4:32 PM - 4:37 PM | Why Is It Important To Avoid “Lost To Follow Up” In AAA Studies: What Measures Can Do So |
Presenter(s):Matthew W. Mell, MD, MS | |
4:38 PM - 4:43 PM | What Is The VORTEC Technique And How Can It Be used To Avoid Large Artery And Aortic Dissection, Clamping And Suturings |
Presenter(s):Mario L. Lachat, MD / Zoran Rancic, MD, PhD, EMBA HSG | |
4:44 PM - 4:49 PM | Treo Endograft From Terumo Aortic For EVAR: Advantages And Status Of Approval In The US An Japan |
Presenter(s):Matthew J. Eagleton, MD | |
4:50 PM - 4:55 PM | Isolated Iliac Artery Aneurysm Do NOT Rupture And Need To Be Treated Until They Are At Least 4 Centimeters In Diameter |
Presenter(s):Christopher J. Smolock, MD | |
4:56 PM - 5:01 PM | How To Safely Stent The Large Fenestration Of A ZFEN Endograft When It Is Crossed By Struts: Indications For Doing So And Late Results |
Presenter(s):Luis A. Sanchez, MD | |
5:02 PM - 5:07 PM | The Mega-Aortic Syndrome: What Is It: When And How Should Be Treated |
Presenter(s):Martin Czerny, MD | |
5:08 PM - 5:14 PM | Panel Discussion |
CAROTID RELATED TOPICS | |
5:14 PM - 5:19 PM | Transcarotid Artery Revascularization (TCAR) Versus Carotid Endarterectomy (CEA): In A Single Center Experienced In Both, Which Is Best And When |
Presenter(s):Zach AbuRahma, DO / Ali F. AbuRahma, MD | |
5:20 PM - 5:25 PM | Intracranial Angiography During TCAR: Technique And Value |
Presenter(s):Peter L. Faries, MD, FACS / Michael L. Marin, MD | |
MORE AORTA RELATED TOPICS | |
5:26 PM - 5:31 PM | Improved Survival After Implementation Of A Large Scale Dedicated Network For Aortic Emergencies: Why The French SOS Aorta System Works |
Presenter(s):Jean-Marc Alsac, MD, PhD | |
5:32 PM - 5:37 PM | How Can The Gore Recapturable C3 Excluder Endograft Be Modified As A PMEG For F/EVAR And TAAA Repair: Technique And Results |
Presenter(s):Wayne W. Zhang, MD | |
5:38 PM - 5:43 PM | The Sandwich-Periscope Technique For Left Subclavian Revascularization With Zone 2 TEVAR: It May Be The Best Way And How To Do It: Technique |
Presenter(s):Sukgu Han, MD | |
5:44 PM - 5:49 PM | Role Of Endovascular And Open Treatment For Mid Aortic Syndrome In Children, Teenagers And Young Adults |
Presenter(s):Ramesh K. Tripathi, MD, FRCS, FRACS | |
5:50 PM - 6:00 PM | Panel Discussion End of Program F |
END OF SESSION 46 | |
Thursday, November 16, 2023
Print Entire 2023 Program:
![]() |
|
SESSION 47 SCHEDULE | |
Thursday
SESSION 47:
EXCITING NEW OR REDISCOVERED TECHNIQUES, DEVICES, CONCEPTS, THE ROLE OF MAJOR FOUNDATIONS
Moderators:TBD
|
|
x | |
6:50 AM - 6:55 AM | Combating Bias In Medical And Vascular Studies And Therapeutic Decision Making: Why It Is Such A Big Deal And What To Do About It |
Presenter(s):Matthew T. Menard, MD | |
6:56 AM - 7:01 AM | Update On Remote Monitoring Of Vascular Graft Function And Other Parameters: Where Is It At And Where Is It Going |
Presenter(s):Richard F. Neville, MD | |
7:02 AM - 7:07 AM | New Wearable Technologies For Telemonitoring Vascular Diseases And Their Treatments: What Are The Current UK Research Priorities: How Will They Improve Patient Care |
Presenter(s):Celia Riga, MD, FRCS | |
7:08 AM - 7:13 AM | TBD |
7:14 AM - 7:19 AM | Update On Tissue Engineered Biological Arterial Grafts (Humacyte) In Various Vascular Beds: How Well Are They Working In Patients: 6-Year Durability Data |
Presenter(s):Todd E. Rasmussen, MD, FACS / Alexander Kersey, MD / Jeffrey H. Lawson, MD, PhD | |
7:20 AM - 7:25 AM | Progress In Developing A Curved Angioplasty Balloon: How It Works And Why It’s Important |
Presenter(s):Timothy A.M. Chuter, DM | |
7:26 AM - 7:31 AM | Panel Discussion |
7:31 AM - 7:36 AM | Relining Occluded Vein Grafts With Viabahn (Gore) Stent-Grafts Or Supera (Abbott) Bare Stents Can Restore Patency And Avoid Thrombolysis Or Clot Removal: Techniques And Results |
Presenter(s):Hans Lindgren, MD, PhD | |
7:37 AM - 7:42 AM | Measuring Aortic Diameters Is Inaccurate And Subjective: Even With Newer Imaging Technology, One Can Make The Diameter What You Want: How Does It Invalidate Many Studies And Trials |
Presenter(s):Janet T. Powell, MD, PhD | |
7:43 AM - 7:48 AM | Provider Skill Is Not Getting Appropriate Attention In The Health Care Value Equation Of Value = Outcome/Cost: Even Within A Specialty All Doctors Are Not Equal: What To Do About It |
Presenter(s):Lars B. Lonn, MD, PhD | |
7:49 AM - 7:54 AM | Performing Transplants In Ukraine During The Russian Invasion: Limitations And Gratification |
Presenter(s):Robert A. Montgomery, MD, D.Phil | |
7:55 AM - 8:00 AM | Effect Of Increased Hydration And Protein Intake On Lower Extremity Arteriosclerotic Ischemia With IC And CLTI: What Is The Evidence And The Mechanism: Will It Change The Game And Decrease The Need For Stents And Bypasses |
Presenter(s):Juan C. Parodi, MD / Samuel Fernandez, MD | |
8:01 AM - 8:06 AM | The Increasing Role And Importance Of Major Foundations In Advancing Critical Research In Vascular Disease: The NovoNordisk Foundation (NNF) And Its Major Support Of BEST-CLI And Early Atherosclerosis Research Is A Prime Example |
Presenter(s):Henrik Sillesen, MD, DMSc | |
8:07 AM - 8:12 AM | Panel Discussion |
END OF SESSION 47 | |
SESSION 48 SCHEDULE | |
Thursday
SESSION 48:
PROGRESS IN FENESTRATED AND BRANCHED EVAR (F/B/EVAR) AND PARALLEL GRAFTS FOR COMPLEX AAAs AND TAAAs; AND RELATED TOPICS
Moderators:TBD
|
|
x | |
8:12 AM - 8:17 AM | The “Shaggy Aorta”: What Is It; How Is It Determined And Quantitated; How Shaggy Does It Have To Be To Matter |
Presenter(s):Germano Melissano, MD | |
8:18 AM - 8:23 AM | The US Aortic Research Consortium (US-ARC): What Is It And How Do Multicenter Systematic Studies Like It With F/B/EVAR Better Answer Clinical Questions: Is There Still Value To Single Center Studies |
Presenter(s):Andres Schanzer, MD | |
8:24 AM - 8:29 AM | Value Of Parallel Endografts In The Management Of TAAAs And Other Aorto-Iliac Pathology: Why Do They Fail And How To Make Them Work |
Presenter(s):David J. Minion, MD | |
8:30 AM - 8:35 AM | Branched EVAR For TAAA Repair Can Be Performed With Only Transfemoral Access Using Steerable Sheaths: How To Stabilize The Distal End Of The Sheath |
Presenter(s):Tilo Koelbel, MD, PhD | |
8:36 AM - 8:41 AM | With Steerable Sheaths Upper Extremity Access With B/EVAR Is Rarely Necessary: Which Sheath Is Best And Pitfalls To Be Avoided |
Presenter(s):Eric L.G. Verhoeven, MD, PhD | |
8:42 AM - 8:47 AM | Why Balloon Expandable Bridging Stent-Grafts Are Best For F/B/EVAR: Which One Is Best And Why: A US Perspective On The Advantages Of The Gore VBX Stent Graft |
Presenter(s):Mark A. Farber, MD | |
8:48 AM - 8:53 AM | Updated Advantages And Disadvantages Of The BeGraft, BeGraft Plus (Bentley) And Advanta (iCAST™ – Getinge) Bridging Stents For F/B/EVAR: Experience With >2000 Target Vessels |
Presenter(s):Eric L.G. Verhoeven, MD, PhD / Athanasios Katsargyris, MD | |
8:54 AM - 8:59 AM | Advantages Of The Cook Inner Branched Endograft For Repair Of TAAAs: Which Is The Best Covered Stent For The Branches |
Presenter(s):Martin J. Austermann, MD / Giovanni B. Torsello, MD | |
9:00 AM - 9:05 AM | New Cook Endograft With Bidirectional Inner Branches For B/EVAR: Advantages And Early Results |
Presenter(s):Nuno V. Dias, MD, PhD | |
9:06 AM - 9:11 AM | With Complex AAAs, When F/B/EVAR; When Parallel Grafts; When Open Repair: All Have Their Pros And Cons |
Presenter(s):Chang Shu, MD | |
9:12 AM - 9:17 AM | How To Deal With Bad Necks Or No Necks In AAAs: We Need All Options: Chimneys, Endoanchors, Fenestrated And Branched Solutions: Case Selection Is The Key: How To Do It |
Presenter(s):Götz M. Richter, MD, PhD | |
9:18 AM - 9:26 AM | Panel Discussion |
9:26 AM - 9:38 AM | Break – Visit Exhibits And Pavilions (2nd and 3rd Floors) |
END OF SESSION 48 | |
SESSION 49 SCHEDULE | |
Thursday
SESSION 49:
MORE PROGRESS IN F/B/EVAR AND PARALLEL GRAFTS FOR COMPLEX AAAs AND TAAAs; AND RELATED TOPICS
Moderators:TBD
|
|
x | |
9:38 AM - 9:43 AM | Update On Aortic Neck Dilatation Occurring After F/EVAR: What Causes It And Is It Harmful To Patients |
Presenter(s):Michael P. Jenkins, MBBS, BSc, MS, FRCS, FEBVS | |
9:44 AM - 9:49 AM | Percutaneous Femoral And Axillary Access For Complex Endovascular AAA Repair: How To Do It Safely And To Safely Downsize Femoral Sheaths To More Rapidly Restore Lower Extremity Flow: Why Is It Important |
Presenter(s):Darren B. Schneider, MD | |
9:50 AM - 9:55 AM | Use Of Parallel Grafts To Treat Common Iliac Aneurysms And Preserve Hypogastric Flow: Techniques, Advantages Over IBDs, Long-Term Results |
Presenter(s):Armando C. Lobato, MD, PhD | |
9:56 AM - 10:01 AM | Advantages And Short-Comings Of Off-The-Shelf Endografts (Industry Made And Parallel) For Complex AAAs And TAAAs: When Are They Helpful And When Not |
Presenter(s):Mark A. Farber, MD | |
10:02 AM - 10:07 AM | DEBATE: The Case Against Ch/EVAR And Parallel Grafts For Complex AAA And TAAA Repairs: F/B/EVAR Is Much Better |
Presenter(s):Adam Beck, MD | |
10:08 AM - 10:13 AM | DEBATE: Nonsense! Ch/EVAR And Parallel Grafts If Done Right Are As Safe And Effective As F/B/EVAR And In Some Cases Better And Cheaper |
Presenter(s):Konstantinos P. Donas, MD | |
10:14 AM - 10:19 AM | Parallel Endografts For Aorto-Iliac Lesions: The Good, The Bad And The Ugly: A Balanced View |
Presenter(s):Grace J. Wang, MD, MSCE | |
10:20 AM - 10:25 AM | Pros And Cons Of Inner Versus Outer Branches In Off-The-Shelf Endovascular TAAA Repair |
Presenter(s):Timothy A. Resch, MD, PhD | |
10:26 AM - 10:31 AM | TBD |
10:32 AM - 10:37 AM | TBD |
10:38 AM - 10:43 AM | Although Some Recommend That F/EVAR Always Include 3 Vessels, 2 Vessel F/EVAR Is Effective And Durable In Some Anatomies: Which Ones, Based On A Single Center Experience And Systematic Review |
Presenter(s):Geert Willem H. Schurink, MD, PhD | |
10:44 AM - 10:52 AM | Panel Discussion |
END OF SESSION 49 | |
SESSION 50 SCHEDULE | |
Thursday
SESSION 50:
A TRIBUTE TO OUR MILITARY AND MILITARY PHYSICIANS: SOME MILITARY HISTORY; TREATMENT OF MILITARY AND CIVILIAN VASCULAR INJURIES AND CONTROL OF HEMORRHAGE; INNOVATIVE TECHNOLOGIES SUPPORTED BY THE DEFENSE DEPARTMENT
Moderators:TBD
|
|
x | |
10:52 AM - 11:02 AM | Battle of Takur Ghar: 20 US Army Airborne Rangers Go To Rescue 7 Navy Seals And 1 Air Force Spotter Attacked By Over 400 Al-Qaeda Forces And 2 Congressional Medal Of Honor Winners Later In That 17-Hour Battle (10-Minute Talk) |
Presenter(s):Wayne F. Yakes, MD | |
11:03 AM - 11:13 AM | Can The US Military Avoid The Damage Of The “Peace Time Effect” And Recent Wokeness Changes To Maintain Real Combat And Surgical Readiness To Win And Avoid Needless Loss Of Life When The Next War Starts (10-Minute Talk) |
Presenter(s):Todd E. Rasmussen, MD, FACS | |
11:14 AM - 11:24 AM | A Vascular Surgeon’s Impressions About The Terrible War In The Ukraine: Analysis Of Vascular Trauma And Late Outcomes Of Vascular Reconstructions In 70 Wounded Soldiers (10-Minute Talk) |
Presenter(s):Andriy O. Nykonenko, MD | |
11:25 AM - 11:30 AM | Humanitarian Vascular Surgery: A Report On The War In Ukraine And The Role Of Non-Governmental Organizations (NGOs) To Deploy Talent To Combat Zones |
Presenter(s):Charles J. Fox, MD, FACS | |
11:31 AM - 11:36 AM | Update Of Endovascular Resuscitation And Trauma Management: Use Of Catheter Based Treatments, Endografts And Other Devices |
Presenter(s):Tal M. Hoerer, MD, PhD | |
11:37 AM - 11:42 AM | Updated Progress And Precautions With REBOA (Resuscitative Endovascular Balloon Occlusion Of The Aorta): How Will They Make It Worthwhile For Battlefield Hemorrhage And Other Conditions |
Presenter(s):Brandon Propper, MD / Zachary M. Arthurs, MD / Todd E. Rasmussen, MD, FACS | |
11:43 AM - 11:48 AM | How Will We Train The Next Generation Of Surgeons To Treat Vascular Trauma: For Military Practice: For Civilian Practice: What Issues Complicate It |
Presenter(s):Paul W. White, MD | |
11:49 AM - 11:54 AM | Major Amputation Prosthetics Can Be Fixed Into Bone: How Does Osteointegration Work And How Is Infection Avoided |
Presenter(s):Zachary M. Arthurs, MD / Todd E. Rasmussen, MD, FACS | |
11:55 AM - 12:00 PM | Panel Discussion |
12:00 PM - 1:00 PM | Lunch Break – Visit Exhibits And Pavilions (2nd and 3rd Floors) |
END OF SESSION 50 | |
SESSION 51 SCHEDULE | |
Thursday
SESSION 51:
PROGRESS IN THE TREATMENT OF RUPTURED INFRARENAL AAAs, COMPLEX AAAs, TAAAs AND RELATED TOPICS
Moderators:TBD
|
|
x | |
1:00 PM - 1:05 PM | Complications After EVAR For Ruptured AAAs: How To Prevent Them And How To Treat Them |
Presenter(s):Tal M. Hoerer, MD, PhD | |
1:06 PM - 1:11 PM | The Frequency Of Ruptured AAAs Is Plummeting: What Is The Reason And Why Is It A Challenge To Training And Treatment |
Presenter(s):Ian Loftus, MD / Pete Holt, MD, PhD | |
1:12 PM - 1:17 PM | Only One-Third Of Ruptured AAA Patients Were Randomized In The 3 RCTs Comparing EVAR With Open Repair: Why Does That Invalidate The Conclusion Of The RCTs That EVAR Is No Better Than Open Repair |
Presenter(s):Thomas L. Forbes, MD | |
1:18 PM - 1:23 PM | Long-Term Results Of The AJAX RCT Comparing EVAR With Open Repair For Ruptured AAAs: Despite Its Flaws, EVAR Wins In The End – Especially In Patients >80 |
Presenter(s):Willem Wisselink, MD | |
1:24 PM - 1:29 PM | Variation In Use Of EVAR Versus Open Repair For Ruptured AAAs Depends On Training And Bias Rather Than Data, Logic Or Facts: EVAR Is Clearly The Best Treatment If It Can Be Done |
Presenter(s):Martin Malina, MD, PhD | |
1:30 PM - 1:35 PM | EVAR Should Be The Standard Of Care For Most Ruptured AAAs: Reasons Why It Is Not So And How To Overcome Them |
Presenter(s):Hans-Henning Eckstein, MD, PhD | |
1:36 PM - 1:41 PM | A New System For Estimating AAA Wall Weakness From Gated Dynamic CT Scans: A Better Way To Predict Rupture Risk (From ViTAA Medical): How Does It Work And Where Does It Stand |
Presenter(s):Randy D. Moore, MD | |
1:42 PM - 1:47 PM | Outcomes Of Ruptured AAA Repair Are Better In High Volume Institutions Both For EVAR And Open Repair: From A Meta-Analysis With >120,000 Cases |
Presenter(s):George A. Antoniou, M.D., PhD, MSc, FEBVS | |
1:48 PM - 1:53 PM | Aortic Endograft Diameter Sizing With Ruptured Aneurysms: Why Is It Different And How To Do It |
Presenter(s):Zoran Rancic, MD, PhD, EMBA HSG | |
1:54 PM - 1:59 PM | With Ruptured Complex AAAs And TAAAs Parallel Grafts Are The Best Treatment: They Are Simpler, More Effective And Less Costly Than Other Treatments |
Presenter(s):Manish Mehta, MD, MPH | |
2:00 PM - 2:06 PM | Panel Discussion |
END OF SESSION 51 | |
SESSION 52 SCHEDULE | |
Thursday
SESSION 52:
MORE NEW DEVELOPMENTS IN RUPTURED AAAs AND TAAAs; WHAT IS AND SHOULD BE HAPPENING WITH AAA SCREENING
Moderators:TBD
|
|
x | |
NEW DEVELOPMENTS IN EVAR SURVEILLANCE AND AAA SCREENING | |
2:06 PM - 2:11 PM | Why We Are Doing More EVAR Surveillance Than Is Needed: The EVAR Surveillance Paradox: From A Meta-Analysis Of 23,000 EVAR Patients |
Presenter(s):George A. Antoniou, M.D., PhD, MSc, FEBVS | |
2:12 PM - 2:17 PM | Update On Current Screening For AAAs In The US: Most Ruptured AAAs Occur In Patients Not Being Screened: How Should US PSTF Recommendations Be Changed And How Should Screening Groups Be Expanded |
Presenter(s):Marc L. Schermerhorn, MD / Thomas F.X. O'Donnell, MD | |
2:18 PM - 2:23 PM | New Developments In AAA Screening: Is It Overused Or Underused: Has It Decreased Rupture Rates In Denmark Or Elsewhere: Should We Change Who Is Being Screened |
Presenter(s):Jes S. Lindholt, MD | |
MORE ABOUT AAA RUPTURES AND THEIR TREATMENT | |
2:24 PM - 2:29 PM | AAA Rupture After EVAR: Endovascular Treatment Is Best In This Setting And How To Do It |
Presenter(s):David T. McGreevy, MD | |
2:30 PM - 2:35 PM | AAA Rupture After EVAR Behaves Differently From De Novo Rupture: How Should Treatment Be Modified In Patients With Post EVAR Ruptures |
Presenter(s):Piotr Szopinski, MD, PhD | |
2:36 PM - 2:41 PM | Update On Treating All (100%) Ruptured Thoracic And Abdominal Aneurysms Endovascularly: A 13-Year Experience Shows It Is The Best Treatment And Lowers The Turndown Rate |
Presenter(s):David T. McGreevy, MD / Thomas Larzon, MD, PhD / Mario L. Lachat, MD / Tal M. Hoerer, MD, PhD | |
2:42 PM - 2:47 PM | Applicability And Results Of Cook t-Branch OTS Endograft In Complex Aortic Aneurysms (Ruptured And Elective) With Narrow Internal Aortic Lumens: Advantages And Limitations |
Presenter(s):Ciro Ferrer, MD, PhD / Rocco Giudice, MD | |
2:48 PM - 2:53 PM | In Situ Laser Fenestration To Facilitate Endograft Treatment Of Ruptured TAAAs: When Is It Needed; How To Do It And Results |
Presenter(s):Stephan Haulon, MD / Dominique Fabre, MD, PhD | |
2:54 PM - 2:59 PM | Role Of In Situ F/EVAR For Treating Ruptured Complex AAAs: How To Do It And Results |
Presenter(s):Sukgu Han, MD / Fred A. Weaver, MD, MMM | |
3:00 PM - 3:05 PM | How Can The Turndown Rate For Invasive Treatment Of Ruptured AAAs Be Decreased And Is It Worthwhile |
Presenter(s):Matthew W. Mell, MD, MS | |
3:06 PM - 3:11 PM | Urgent And Emergent Treatment Of Symptomatic And Ruptured Aortic Pathologies Using Physician Modified Endografts (PMEGs) Based On 3D Aortic Models: Is This A Limited Or Generalizable Technique |
Presenter(s):Benjamin W. Starnes, MD | |
3:12 PM - 3:17 PM | Update On Advances In Treatment Of Abdominal Compartment Syndrome Associated With Ruptured AAAs: When And How To Treat Medically And When And How To Treat With Opening The Abdomen |
Presenter(s):Martin Bjorck, MD, PhD | |
3:18 PM - 3:30 PM | Panel Discussion And Break (Visit Exhibits And Pavilions – 2nd and 3rd Floors) |
END OF SESSION 52 | |
SESSION 53 SCHEDULE | |
Thursday
SESSION 53:
EXCITING NEW OR UPDATED CONCEPTS, TECHNIQUES AND TREATMENTS
Moderators:TBD
|
|
x | |
3:30 PM - 3:35 PM | The Serranator® Balloon Catheter (From Cagent Vascular) For Vessel Prep In BTK Arteries: It Makes Microserrations, Prevents Dissections Lessens Elastic Recoil With PTA: Current Status |
Presenter(s):Steven Kum, MD / Andrew Holden, MBChB | |
3:36 PM - 3:41 PM | The No Intervention Option For Treatment Is More Commonly Elected For Women Than Men With CLTI, AAAs, Ruptured AAAs And Thoracic Aneurysms: It Is Wrong Headed And Unfair: From The WARRIORS Trial |
Presenter(s):Richard J. Powell, MD | |
3:42 PM - 3:47 PM | TBD |
3:48 PM - 3:53 PM | The CHOCO-CABANA RCT Shows The Chocolate PTA Balloon (From Medtronic) Sustained Increased Lumen Gain Compared To POBA For BTK Lesions |
Presenter(s):Gunnar Tepe, MD / Andrew Holden, MBChB / Thomas Zeller, MD | |
3:54 PM - 3:59 PM | Transradial Approaches With The Terumo R2P System Enable Endovascular Treatment Of Complex Renal, Visceral, And Lower Extremity Stenotic And Occlusive Lesions Including CTOs: Do They Work For Lesions Below The Knee |
Presenter(s):David O'Connor, MD | |
4:00 PM - 4:05 PM | Improving The Function Of A Hybrid Room: What Are The Elements And How Does The “OR Black Box System” Help To Improve Operator Performance And Decrease Radiation Exposure |
Presenter(s):Isabelle Van Herzeele, MD, PhD | |
4:06 PM - 4:11 PM | Update On A Clampless Sutureless Technique For Performing Difficult Arterial Anastomoses Using Endograft Connectors: The VORTEC Technique – Useful When Arterial Dissection, Control And Suturing Are Challenging Or Impossible As With Heavily Calcified Arteries |
Presenter(s):Mario L. Lachat, MD | |
4:12 PM - 4:17 PM | IVUS Studies Before And After PTAs With The Ultrascore Scoring Balloons (From BD) Show The Benefits Of Such Balloons And How They Work |
Presenter(s):Robert E. Beasley, MD, FSIR, FSCAI | |
4:18 PM - 4:23 PM | Femoral Vein Grafts For Arterial Procedures: How To Harvest Them Safely And Expeditiously Without Consequences To The Donor Limb: When Can They Be Uniquely Beneficial |
Presenter(s):Timur P. Sarac, MD | |
4:24 PM - 4:31 PM | Panel Discussion |
END OF SESSION 53 | |
SESSION 54 SCHEDULE | |
Thursday
SESSION 54:
PROGRESS IN RADIATION SAFETY AND MORE NEW CONCEPTS, DEVICES AND TECHNIQUES
Moderators:TBD
|
|
x | |
WHAT’S NEW IN RADIATION SAFETY | |
4:32 PM - 4:37 PM | Myths And Facts Regarding Radiation Protection And Safety: Imperfections In Protection From Leaded Glasses And Light Weight Leaded Gowns |
Presenter(s):Lindsay Machan, MD | |
4:38 PM - 4:43 PM | Cancer Risk To Patients And Operators From Radiation Exposure From EVAR Peri- And Post-Operatively: Role Of Radiation Sparing Technologies |
Presenter(s):Bijan Modarai, PhD, FRCS | |
4:44 PM - 4:49 PM | Small Tips And Modifications In Radiation Safety Can Make A Huge Impact On Staff Exposure: What Are They |
Presenter(s):Maarit Venermo, MD, PhD | |
4:50 PM - 4:56 PM | Panel Discussion |
NEW CONCEPTS, ETC. | |
4:56 PM - 5:01 PM | With Esophageal Cancer, When Is Prophylactic TEVAR Indicated To Prevent An Aorto-Esophageal Fistula: It Improves Palliation But Does It Improve Survival |
Presenter(s):I-Hui Wu, MD, PhD | |
5:02 PM - 5:07 PM | Endovascular Emergency Treatment Of Carotid Blowout From Head And Neck Cancer Or Carotid Patch Infections: Planning, Preparation And Technical Tips Are Essential |
Presenter(s):Michael B. Silva, Jr., MD | |
5:08 PM - 5:13 PM | What’s New In Gene And Stem Cell Therapy For No Option CLTI In 2023 |
Presenter(s):Richard J. Powell, MD | |
5:14 PM - 5:19 PM | Endovascular Options For The Control Of Submassive Hemopysis: When And How To Do It: It Is Life Saving |
Presenter(s):Jacob Cynamon, MD, FACR, FSIR | |
5:20 PM - 5:25 PM | Management Of Pediatric Vascular Trauma: Evolving Endovascular Strategies, Expanded Device Availability, Technical Tips And How To Deal With Spasm |
Presenter(s):Dawn M. Coleman, MD | |
5:26 PM - 5:31 PM | The Aortyx Aortic Patch: A More Compliant Way To Seal Aortic Defects: A New Endovascular Approach: How Does It Work, Improved Delivery System And Progress To Date |
Presenter(s):Vicente Riambau, MD, PhD | |
5:32 PM - 5:37 PM | Results From The AFX2-LIVE Registry: An Experience With The Outcomes Of: >500 AFX EVAR Cases: Benefits, Complications And Conversions |
Presenter(s):Francesco Speziale, MD / Pasqualino Sirignano, MD | |
5:38 PM - 5:43 PM | Digital Patient Data: Artificial Intelligence (AI), Machine Learning (ML) And Sensor Technology In The New Era Of Research And Clinical Medicine: What Are They And Why You Better Get Ready |
Presenter(s):Peter A. Schneider, MD | |
5:44 PM - 5:52 PM | Panel Discussion End of Program G |
END OF SESSION 54 | |
SESSION 55 SCHEDULE | |
Thursday
SESSION 55:
NEW OR IMPROVED DEVICES FOR INFRARENAL AAA REPAIR WITH STANDARD EVAR
Moderators:TBD
|
|
x | |
7:00 AM - 7:05 AM | Real World Outcomes With The TREO Endograft (Terumo Aortic): Results From The TIGER Registry |
Presenter(s):Vicente Riambau, MD, PhD | |
7:06 AM - 7:11 AM | Update On The Gore Conformable Excluder With Variable Neck Angulation Control For AAAs: Does It Enable EVARs In Patients With Otherwise Unsuitable Necks: Update On Status Of The IDE Trial And FDA Approval |
Presenter(s):Robert Y. Rhee, MD | |
7:12 AM - 7:17 AM | European Status Of The Gore Conformable Excluder For EVAR: 3-Year Results From The EXCEL Registry: CE Marked Since 2016 |
Presenter(s):Colin D. Bicknell, MD, FRCS / Marc R.H.M. van Sambeek, MD, PhD | |
7:18 AM - 7:23 AM | Altura Endograft With Kissing Proximal Stents For Standard EVAR: Advantages And Limitations: From An Updated Experience With >150 Patients And 5-Year Follow-Up |
Presenter(s):Dainis K. Krievins, MD | |
7:25 AM - 7:29 AM | Advantages And Limitations Of The Cook ZENITH Alpha (Low Profile) Endograft For EVAR: Based On 3-Year Results Of The European Multicenter ZEPHYR TRIAL |
Presenter(s):Philippe W.M. Cuypers, MD, PhD / Marc R.H.M. van Sambeek, MD, PhD / Dittmar Boeckler, MD | |
7:30 AM - 7:35 AM | Panel Discussion |
7:36 AM - 7:41 AM | How And Why Do The Endurant Endograft Results For EVAR In France Differ From The Global Results: What Are The Implications |
Presenter(s):Frank R. Arko, MD / Jean Pierre Becquemin, MD, FRCS | |
7:42 AM - 7:47 AM | AAA Repairs With The Endurant Endograft Outside The IFU Can Provide 7 Acceptable Results In Some Patients: When Is This So And When Not: From The EAGLE Registry |
Presenter(s):Marc R.H.M. van Sambeek, MD, PhD | |
7:48 AM - 7:53 AM | Head To Head Comparison Of Endurant And Excluder Endografts For EVAR In Challenging Asian AAA Anatomy |
Presenter(s):Naoki Fujimura, MD, PhD | |
7:54 AM - 7:59 AM | AFX 2 Anatomically Fixed Endografts For AAA Repair: The LEOPARD RCT 5-Year Results Show It Has Similar Outcomes To Other Widely Used Proximally Fixed Endografts |
Presenter(s):Christopher J. Kwolek, MD, MBA | |
8:00 AM - 8:05 AM | Why AFX Endografts Work Well In Conical (Flared) AAA Necks: Favorable 3-Year Results And Are There Disadvantages |
Presenter(s):Naoki Fujimura, MD, PhD | |
8:06 AM - 8:11 AM | Panel Discussion |
END OF SESSION 55 | |
SESSION 56 SCHEDULE | |
Thursday
SESSION 56:
NEW OR UPDATED DEVICES FOR STANDARD EVAR, EVAS (ENDOVASCULAR ANEURYSM SEALING) AND F/EVAR; ENDOGRAFTS FOR TREATMENT OF CONNECTIVE TISSUE DISORDERS
Moderators:TBD
|
|
x | |
8:12 AM - 8:17 AM | Alto Endograft (From Endologix) For Standard EVAR: This Latest Modification Of The Ovation Endograft Has More Proximal Polymer Sealing Rings: Results From The ELEVATE Trial And 4+-Year Results From The New Zealand Experience Show Advantages: What Is The JAGUAR RCT |
8:18 AM - 8:23 AM | Update On The Alto Ultra Low-Profile Endograft With Adaptive Sealing Technology: From The ALTAIR Registry With Long-Term Results |
Presenter(s):Gianmarco de Donato, MD | |
8:24 AM - 8:29 AM | Experience With The Nellix Endograft In 120 Patients With Up To 10 Years Follow-Up: What Is The Devices’ Future |
Presenter(s):Dainis K. Krievins, MD | |
8:30 AM - 8:35 AM | Update On The Incraft Endograft (From Cordis) For Standard Infrarenal EVAR: Is Its Low Profile An Advantage Or Limitation |
Presenter(s):Giovanni B. Torsello, MD / Matteo Orrico, MD / Nicola Mangialardi, MD | |
F/EVAR RELATED TOPICS | |
8:36 AM - 8:41 AM | Technical Tips To Perform F/EVAR Through Unilateral Iliac Access: Useful When Contralateral Access Is Impossible |
Presenter(s):Barend M.E. Mees, MD, PhD, FEBVS | |
8:42 AM - 8:47 AM | Update On Multicenter Results With F/EVAR Using The Fenestrated Anaconda (Terumo Aortic) Endograft: Advantages And Limitations: From The Global FACT Registry |
Presenter(s):Clark J. Zeebregts, MD, PhD / Michel M.P. Reijnen, MD, PhD / Afshin Assadian, MD | |
ENDOVASCULAR AORTIC REPAIRS FOR CONNECTIVE TISSUE DISORDERS | |
8:48 AM - 8:53 AM | Enodvascular Repairs In Genetic Connective Tissue Aortopathies |
Presenter(s):Sherene Shalhub, MD, MPH | |
8:54 AM - 8:59 AM | F/B/EVAR In Patients With Connective Tissue Disorders: When And When Not: How Well Do They Work And When Not To Do Them |
Presenter(s):Piergiorgio Cao, MD, FRCS | |
9:00 AM - 9:05 AM | Value Of Endo TAAA Repair In Patients With Connective Tissue Disorders And Why Is The Gap Between Fenestration And Aortic Wall Important In F/EVAR |
Presenter(s):Gustavo S. Oderich, MD FACS | |
9:06 AM - 9:16 AM | Panel Discussion |
9:16 AM - 9:26 AM | Break – Visit Exhibits And Pavilions (2nd and 3rd Floors) |
END OF SESSION 56 | |
SESSION 57 SCHEDULE | |
Thursday
SESSION 57:
NEW OR IMPROVED DEVICES FOR THE ASCENDING AORTA, THE AORTIC ARCH OR NEAR THE ARCH
Moderators:TBD
|
|
x | |
9:26 AM - 9:31 AM | Changes In The Aortic Valve And Aortic Morphometrics After Ascending Aorta And Arch Endograft Placement |
Presenter(s):Jean Bismuth, MD / Ross Milner, MD | |
9:32 AM - 9:37 AM | Updated European Experience With The Custom Relay Ascending Aorta Endograft (Terumo Aortic) |
Presenter(s):Vicente Riambau, MD, PhD / Afshin Assadian, MD / Mo S. Hamady, MD, FRCR, EBIR, FSIR | |
9:38 AM - 9:43 AM | Status In The US Of The Relay Branch Investigational Device For Repair Of Aortic Arch Lesions: How Many Branches Can And Should Be Revascularized: Advantages And Limitations |
Presenter(s):Eric E. Roselli, MD / Luis A. Sanchez, MD | |
9:44 AM - 9:49 AM | Nexus OTS Endograft From Endospan For Treating Zone 0 And 1 Lesions Of The Aortic Arch: How Does It Work And 4-Year Clinical Results: Status In The US |
Presenter(s):Mario L. Lachat, MD / Ross Milner, MD / Jean M. Panneton, MD / Andrew Holden, MBChB / Daniel G. Clair, MD / Nicola Mangialardi, MD | |
9:50 AM - 9:55 AM | Status Of And When And How To Use The Gore Conformable CTAG Endograft With Variable Angulation Control Optimally: Advantages And Limitations |
Presenter(s):Sukgu Han, MD | |
9:56 AM - 10:02 AM | Panel Discussion |
END OF SESSION 57 | |
SESSION 58 SCHEDULE | |
Thursday
SESSION 58:
NEW OR IMPROVED DEVICES FOR THORACIC AORTIC LESION REPAIRS (TEVAR) AND FOR THORACOABDOMINAL ANEURYSM (TAAA) REPAIRS
Moderators:TBD
|
|
x | |
DEVICES FOR TEVAR | |
10:02 AM - 10:07 AM | Low Profile Devices For TEVAR: And B/EVAR Disadvantages And Advantages Based On A 10-Year Experience With Matched Patients |
Presenter(s):Giovanni B. Torsello, MD | |
10:08 AM - 10:13 AM | Long-Term Results With The Cook ZENITH Alpha Thoracic Endograft For TEVAR In More Than 500 Patients In A Real World 10-Year Experience |
Presenter(s):Germano Melissano, MD / Roberto L.V. Chiesa, MD | |
10:14 AM - 10:19 AM | A Modified Candy Plug Technique For False Lumen Treatment After TEVAR For TBAD |
Presenter(s):Ali Azizzadeh, MD | |
10:20 AM - 10:25 AM | TBD |
10:26 AM - 10:31 AM | Urgent And Emergent Endovascular Repair Of Complex AAAs And TAAAs Are Possible With Off-The-Shelf (OTS) Devices And PMEGSs: When Are OTS Devices Preferable |
Presenter(s):Bernardo C. Mendes, MD | |
10:32 AM - 10:37 AM | Panel Discussion |
10:37 AM - 10:42 AM | The Relay Pro (Terumo Aortic) Endograft For TEVAR And Its Advantages In Treating TBADs: Why Is It Better Than The Older Relay Plus Device |
Presenter(s):Steven D. Abramowitz, MD / Edward Y. Woo, MD | |
10:43 AM - 10:48 AM | Patient Specific Custom Designed Relay Pro Endografts (Terumo Aortic): How Do They Work And What Are Their Advantages In Various Circumstances |
Presenter(s):David M. Williams, MD | |
10:49 AM - 10:54 AM | Relay Custom-Made Endografts (Terumo Aortic) For TEVAR: Why Do They Provide Better Wall Apposition For Sealing |
Presenter(s):Fadi Taher, MD / Afshin Assadian, MD | |
NEW OR IMPROVED ENDO DEVICES FOR TAAA REPAIRS | |
10:55 AM - 11:00 AM | The Novel Artivion (Formerly CryoLife/Jotec) Off-The-Shelf (OTS) Inner Branched Device For TAAAs: Results And Why Is It Better Than Outer Branched OTS Devices: Are There Limitations |
Presenter(s):Lee Bouwman, MD, PhD, MSc | |
11:01 AM - 11:16 AM | Colt Concept And Its Evolution Towards The Inner Branch Endograft For Complex AAAs: Colt 2.0: How It Works And Early Outcomes |
Presenter(s):Piotr Szopinski, MD, PhD | |
11:07 AM - 11:12 AM | To Treat Complex TAAAs: Combination Of Relay (Terumo) TEVAR And Fenestrated And Branched EVAR Best: Technical Tips And Outcomes |
Presenter(s):Mo S. Hamady, MD, FRCR, EBIR, FSIR | |
11:13 AM - 11:18 AM | Panel Discussion |
11:19 AM - 11:24 AM | Preloaded Fenestrated Endografts With A Modified Biport Handle (From Cook): A Way To Make F/EVAR Easier: Results From An International Multicenter Study |
Presenter(s):Nikolaos Tsilimparis, MD, PhD | |
11:25 AM - 11:30 AM | Comparison Of The Cook t-Branch OTS Endograft Device With The E-nside (Artivion) Multibranched Device For Juxta- And Pararenal AAAs: Advantages And Limitations Of Each |
Presenter(s):Matteo Orrico, MD / Nicola Mangialardi, MD | |
11:31 AM - 11:36 AM | Comparison Of 2 OTS Endografts For Urgent TAAA Repairs: E-nside (Artivion) Versus t-Branch (Cook): Advantages And Disadvantages Of Each |
Presenter(s):Luca Bertoglio, MD / Roberto L.V. Chiesa, MD / Germano Melissano, MD | |
11:37 AM - 11:42 AM | Valiant Manifold OTS Endograft Device (Medtronic) For Repairing TAAAs: How Does It Work; Update On Clinical Experience And Future Prospects |
Presenter(s):Murray L. Shames, MD | |
11:43 AM - 11:48 AM | Innovative Treatment Of The Thoracoabdominal And Pararenal Aortic Aneurysms Using Treovance Endografts (Terumo) And Parallel VBX Stent-Grafts (Gore) |
Presenter(s):James F. McKinsey, MD | |
11:49 AM - 11:54 AM | Is There A Role For Hyperbaric Oxygen Therapy In Preventing Or Treating Spinal Cord Ischemia After TAAA Repair |
Presenter(s):Thomas F. Lindsay, MDCM, FRCS | |
11:55 AM - 12:00 PM | Panel Discussion |
12:00 PM - 1:00 PM | Lunch Break – Visit Exhibits And Pavilions (2nd and 3rd Floors) |
END OF SESSION 58 | |
SESSION 59 SCHEDULE | |
Thursday
SESSION 59:
NEW OR UPDATED INFORMATION ON RE-ENTRY DEVICES, LOWER EXTREMITY PROSTHETIC GRAFTS (SEE ALSO SESSION 28), PERIGRAFT SEROMA AND VALUE OF A PROSTHETIC PERIGRAFT SIROLIMUS PATCH
Moderators:TBD
|
|
x | |
A NEW LOOK AT RE-ENTRY DEVICES | |
1:00 PM - 1:05 PM | Pros And Cons Of Re-Entry Devices In Treating CTOs: Why, Where And When To Use Them |
Presenter(s):Maria A. Ruffino, MD, EBIR, FCIRSE | |
PROSTHETIC GRAFTS | |
1:06 PM - 1:11 PM | Final 5-Year Results Of The ZILVERPASS RCT Comparing Prosthetic PTFE Bypasses With Zilver PTX (Cook) Stents To Treat Long Fempop Lesions: Clinical And Financial Results And Their Implications |
Presenter(s):Michel J. Bosiers, MD / Marc Bosiers, MD | |
1:12 PM - 1:17 PM | The BioMimics 3D Spiral Flow Prosthetic Graft From Veryan Medical: Does It Prevent Neointimal Hyperplasia In Leg Bypasses Or A-V Access |
Presenter(s):Hosam F. El Sayed, MD | |
1:18 PM - 1:23 PM | Heparin Coated (Propaten) PTFE Grafts (Gore) Versus Autologous Vein Grafts For Bypasses To Targets Above And Below The Knee: The Heparin Coated Grafts Are Better And Worth The Cost: Based On A Propensity Matching Analysis |
Presenter(s):David J. Dexter, MD | |
1:24 PM - 1:29 PM | Perigraft Seromas After PTFE Lower Extremity And Aortic Arterial Grafts: Frequency, Etiology And What To Do About Them |
Presenter(s):Jae S. Cho, MD | |
1:30 PM - 1:35 PM | Update On External Sirolimus Patch Wrap-Arounds For PTFE Graft Anastomoses: Do They Decrease Neointimal Hyperplasia |
Presenter(s):Sriram S. Iyer, MD; FACC | |
1:36 PM - 1:42 PM | Panel Discussion |
END OF SESSION 59 | |
SESSION 60 SCHEDULE | |
Thursday
SESSION 60:
NEW OR IMPROVED ENDOVASCULAR DEVICES FOR LOWER EXTREMITY TREATMENTS: ATHERECTOMY, STENTS, TACKS, ACCESSORIES, ETC. (SEE ALSO SESSIONS 23-27)
Moderators:TBD
|
|
x | |
ATHERECTOMY RELATED TOPICS | |
1:42 PM - 1:47 PM | A Balanced View Of Atherectomy In Ambulatory Surgicenters (ASCs) And OBLs In 2023: Are There Differences And Is The Procedure Overused |
Presenter(s):Krishna Jain, MD | |
1:48 PM - 1:53 PM | Atherectomy: When Is It The Best Vessel Prep: What Are Its Complications: How To Prevent And Treat Them: Which Device Is Best |
Presenter(s):Theodosios Bisdas, MD | |
1:54 PM - 1:59 PM | Value And Limitations Of The 355 nm Auryon B-Laser™ (From AngioDynamics) For The Treatment Of Infrainguinal Atherosclerotic Disease: Results And How It Can Help Facilitate The Safe Crossing Of Otherwise Uncrossable Lesions |
Presenter(s):Luis R. Leon, MD, RVT, FACS | |
2:00 PM - 2:05 PM | Orbital And Laser Atherectomy: Indications, Advantages And Precautions With Above And Below Knee De Novo Lesions And ISR |
Presenter(s):Craig M. Walker, MD | |
2:06 PM - 2:11 PM | The Value Of Directional Atherectomy Followed By DCBs For Long Calcified Fempop Lesions As Demonstrated By The Results Of The REALITY Trial |
Presenter(s):Brian G. DeRubertis, MD | |
2:12 PM - 2:17 PM | Value of Wingman Catheter (Reflow Medical) For Crossing Difficult Lesions: How Does It Work And Results |
Presenter(s):John R. Laird, MD | |
2:18 PM - 2:23 PM | New Dedicated Special Tools And Devices To Facilitate Trans-Radial Access For Lower Extremity Lesion Treatments: How Far Distally Can It Be Effective |
Presenter(s):Ramon L. Varcoe, MBBS, MS, FRACS, PhD, MMed (ClinEpi) | |
2:24 PM - 2:30 PM | Panel Discussion |
NEW INFORMATION ON STENTS | |
2:30 PM - 2:35 PM | Advantages Of Supera (Vasculomimetic – VMI; From Abbott) Stent For Complex Fempop Occlusive Lesions: Technical Tips: They Work Even In The Subintimal Position |
Presenter(s):Erwin Blessing, MD | |
2:36 PM - 2:41 PM | Updated Value Of The Supera VMI Stent For Common Femoral Artery (CFA) Occlusive Lesions: Better Than Endarterectomy: 3-Year Results And Status Of The SUPERSURG RCT (Versus Open Surgery) |
Presenter(s):Yann Gouëffic, MD, PhD | |
2:36 PM - 2:42 PM | Updated Value Of The Supera VMI Stent For Common Femoral Artery (CFA) Occlusive Lesions: Better Than Endarterectomy: 3-Year Results And Status Of The SUPERSURG RCT (Versus Open Surgery) |
Presenter(s):Yann Gouëffic, MD, PhD | |
2:42 PM - 2:47 PM | Why Are Stents In The Common Femoral Artery (CFA) Bad News: Standard Open Surgery Is Still The Best Option For Treating CFA Lesions |
Presenter(s):Domenico Valenti, DMChir, PhD, FRCS, FRCS(Ed), FEBVS | |
2:48 PM - 2:53 PM | Temporary Stent Assisted DCB Angioplasty In BTK Lesions With The Spur Spiked Stent System (Reflow Medical): Update On The DEEPER OUS Trial |
Presenter(s):Thomas Zeller, MD | |
2:54 PM - 2:59 PM | 10-Year Experience With Transcatheter Arterialization Of The Deep Veins: My Early Failures; The Lessons I Have Learned; How I Do Them Now With More Success: Can It Be Improved More: Value Of The LimFlow Device |
Presenter(s):Steven Kum, MD | |
3:00 PM - 3:06 PM | Panel Discussion |
3:06 PM - 3:18 PM | Break – Visit Exhibits And Pavilions (2nd and 3rd Floors) |
END OF SESSION 60 | |
SESSION 61 SCHEDULE | |
Thursday
SESSION 61:
NEW OR IMPROVED ENDOVASCULAR DEVICES FOR LOWER EXTREMITY TREATMENTS: ANGIOPLASTY BALLOONS
Moderators:TBD
|
|
x | |
3:18 PM - 3:23 PM | 4-Year Results Of TOBA II BTK Trial Of The Tack Device (From Philips) To Decrease Dissections With Balloon Angioplasty Of BTK Lesions Show Safety And 80% Patency: Is It Cost Effective |
Presenter(s):Patrick J. Geraghty, MD | |
3:24 PM - 3:29 PM | Value Of High-Pressure Non-Compliant Balloons For BTK Arterial Lesion Treatment: Why They Work Better And Other Technical Tips |
Presenter(s):Steven Kum, MD | |
3:30 PM - 3:35 PM | How To Obtain Retrograde Access Through The Medial Or Lateral Plantar Arteries |
Presenter(s):Jos C. van den Berg, MD, PhD | |
3:36 PM - 3:41 PM | Value Of The Passeo-18Lux DCB For Treating BTK Lesions With Or Without Bare Metal Stents |
Presenter(s):Gunnar Tepe, MD | |
3:42 PM - 3:47 PM | Unfavorable Balloon (Candy) Wrap Can Cause Dissections With Angioplasty: What Is The Mechanism: How Can It Be Recognized And Dissection Avoided: When Does Dissection Have To Be Treated And When Not |
Presenter(s):Jos C. van den Berg, MD, PhD | |
3:48 PM - 3:53 PM | The Importance Of Dissection In Angioplasty Treatment Of BTK Lesions: How To Prevent And Treat Such Dissections: The Value Of Tacks (From Philips) |
Presenter(s):Andrew Holden, MBChB | |
3:54 PM - 3:59 PM | Chocolate Touch DCBs (From TriReme Medical): How Do They Work, Advantages And Updated Clinical Results From The CHOCALATE TOUCH Trial |
Presenter(s):Thomas Zeller, MD / Andrew Holden, MBChB | |
4:00 PM - 4:06 PM | Panel Discussion |
END OF SESSION 61 | |
SESSION 62 SCHEDULE | |
Thursday
SESSION 62:
NEW OR IMPROVED DEVICES AND TECHNIQUES TO PREVENT OR TREAT ENDOLEAKS OR DEVICE MIGRATION: ENDOANCHORS, ETC.
Moderators:TBD
|
|
x | |
4:06 PM - 4:11 PM | Endoanchors Improve Seal Zones And Outcomes With Fenestrated Endografts: When Should They Be Used And Technical Tips |
Presenter(s):Shadi J. Abu-Hallmah, MD | |
4:12 PM - 4:17 PM | New Developments From The ANCHOR Registry With Over 5 Years Of Follow-Up Show The Value Of Endoanchors (Medtronic) When Used Prophylactically For Certain Indications Prevent Endoleaks And Migration: Large Diameter Necks Are One Of Those Indications |
Presenter(s):William D. Jordan Jr., MD | |
4:18 PM - 4:23 PM | New Developments From The ANCHOR Registry With >5 Years Follow-Up Show That Endoanchors Can Be Used To Treat Endoleaks And Migration Effectively In Hostile Neck Anatomy: The Proof |
Presenter(s):Jean-Paul de Vries, MD, PhD | |
4:24 PM - 4:29 PM | Update On Vesteck – The Next Generation Of Endoanchor (Endosuturing) Technology: How Does It Work; How Is It Different From Endoanchors And Early Clinical Results |
Presenter(s):Sean P. Lyden, MD / Dainis K. Krievins, MD / David H. Deaton, MD, FACS | |
4:30 PM - 4:35 PM | Balloon Optimized Molding For Better Deployment And Sealing Of Ovation Alto (From Endologix) Low Profile Endografts For EVAR: How To Do It And How It Helps Prevent Endoleaks And Migration |
Presenter(s):David J. Minion, MD | |
4:36 PM - 4:42 PM | Panel Discussion |
END OF SESSION 62 | |
SESSION 63 SCHEDULE | |
Thursday
SESSION 63:
NEW OR IMPROVED ENDOVASCULAR DEVICES FOR CLOT REMOVAL OR EMBOLIZATION (SEE ALSO SESSION 30)
Moderators:TBD
|
|
x | |
CLOT REMOVING DEVICES | |
4:42 PM - 4:47 PM | Newer Pharmaco-Mechanical Endovascular Clot Removal Systems: When And Why Is Each Device Best To Use |
Presenter(s):Guillermo A. Escobar, MD | |
4:48 PM - 4:53 PM | Catheter Based Vacuum Assisted Thrombectomy With The Indigo Aspiration System From Penumbra For Acute Limb Ischemia: How Does It Work: Advantages And Limitations: From A Multicenter Study: Key Findings From The INDIAN Trial |
Presenter(s):Gianmarco de Donato, MD / Carlo Setacci, MD | |
4:54 PM - 4:59 PM | Improved Mechanical Catheter And Computer Based Clot Removal Indigo Systems From Penumbra: Modulated Pulsed Aspiration Technology (Lightening Bolt And Thunder Bolt) For The Treatment Of Acute Arterial Clot: How It Works And Why It Improves Clot Removal In Various Vascular Beds |
Presenter(s):James F. Benenati, MD / Carlo Setacci, MD | |
5:00 PM - 5:05 PM | Technical Tips For Effective Coil Embolization: Importance Of Dense Packing; Why Non-Fibered Coils Are Better Than Fibered Coils |
Presenter(s):James F. Benenati, MD / Constantino Pena, MD | |
5:06 PM - 5:11 PM | How To Treat Type 1A Endoleaks And Persistent Enlarging False Lumens After TEVAR For TBAD: Coils, Plugs And New Polymer Based Options: When Will They Work; When Will They Not: Technical Tips |
Presenter(s):Mazin Foteh , MD | |
5:12 PM - 5:17 PM | Caterpillar™ Embolic Plug (From BD): How Does It Work: Advantages And Clinical Results |
Presenter(s):Andrew Holden, MBChB | |
5:18 PM - 5:23 PM | Newer Vascular Occlusion Device: The Azur Device: How Does It Work And Advantages And Limitations |
Presenter(s):Karthik Kasirajan, MD | |
5:24 PM - 5:29 PM | How To Insert Large Vessel Embolization Devices (PODs) Through Low Profile Access |
Presenter(s):Frank R. Arko, MD | |
5:30 PM - 5:35 PM | Update On Onyx Liquid Embolic Occlusive Agent (From Medtronic): When And Where Is It Advantageous: Technical Tips For Use |
Presenter(s):Tal M. Hoerer, MD, PhD | |
5:36 PM - 5:41 PM | Update On A New Liquid Embolic Agent (Lava LES) To Control Bleeding; How Does It Work, Advantages And Pivotal Trial Results |
Presenter(s):Mahmood Razavi, MD | |
5:42 PM - 5:52 PM | Panel Discussion End of Program H |
END OF SESSION 63 | |
SESSION 64 SCHEDULE | |
Thursday
SESSION 64:
PROGRAM TO BE DETERMINED
Moderators:TBD
|
|
x | |
END OF SESSION 64 | |
SESSION 72 SCHEDULE | |
Thursday
SESSION 72:
PROGRAM TO BE DETERMINED
Moderators:TBD
|
|
x | |
END OF SESSION 72 | |